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Current vaccine development disregards human immune ontogeny, relying on animal
models to select vaccine candidates targeting human infants, who are at greatest risk
of infection worldwide, and receive the largest number of vaccines. To help accelerate
and de-risk development of early-life effective immunization, we engineered a human
age-specific microphysiologic vascular-interstitial interphase, suitable for pre-clinical
modeling of distinct age-targeted immunity in vitro. Our Tissue Constructs (TCs) enable
autonomous extravasation of monocytes that undergo rapid self-directed differentiation
into migratory Dendritic Cells (DCs) in response to adjuvants and licensed vaccines such
as Bacille Calmette-Guérin (BCG) or Hepatitis B virus Vaccine (HBV). TCs contain a
confluent human endothelium grown atop a tri-dimensional human extracellular matrix
substrate, employ human age-specific monocytes and autologous non heat-treated
plasma, and avoid the use of xenogenic materials and exogenous cytokines.
Vaccine-pulsed TCs autonomously generated DCs that induced single-antigen recall
responses from autologous naïve and memory CD4+ T lymphocytes, matching study
participant immune-status, including BCG responses paralleling donor PPD status,
BCG-induced adenosine deaminase (ADA) activity paralleling infant cohorts in vivo, and
multi-dose HBV antigen-specific responses as demonstrated by lymphoproliferation and
TCR sequencing. Overall, our microphysiologic culture method reproduced age- and
antigen-specific recall responses to BCG and HBV immunization, closely resembling
those observed after a birth immunization of human cohorts in vivo, offering for the
first time a new approach to early pre-clinical selection of effective age-targeted vaccine
candidates.
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INTRODUCTION
Infections are most frequent at the extremes of life, especially
among newborns, reflecting age-specific differences in immunity
(1). Other than provision of clean drinking water, immunization
is the most effective means of preventing infections; however,
due to distinct early life immunity, many vaccines are also not
optimally immunogenic, requiring multiple booster doses to
achieve protection. Indeed, despite current vaccination efforts,
>2 million neonates (<4 weeks of age) and young infants (<6
months of age) die of preventable infections yearly worldwide.
Currently, only Hepatitis B Vaccine (HBV), Oral Poliovirus
Vaccine (OPV), and the tuberculosis vaccine Bacille Calmette-
Guérin (BCG) have been licensed for neonatal use worldwide (2).
Contrasting with the urgency of effective early-life immunization,
vaccine development is painfully slow and costly, averaging
15 years to approval (3). Furthermore, early-stages of vaccine
development do not typically consider human immune ontogeny
and rely heavily on genetically- and immunologically- divergent
animal models (4, 5) to select vaccine candidates targeting human
infants; a pre-clinical process anticipated to affect end-point
effectiveness and therefore, its successful transition to market.
Thus, new pre-clinical human immune models informing age-
targeted vaccine effectiveness in vitro could help accelerate,
enhance and de-risk vaccine development, including effective
single-dose neonatal vaccines, increasing coverage, reducing
infant vulnerability, and yielding major public health benefits (2).
In vivo, effectiveness of artificial immunization relies
on the necessary detection and tolerance to self-antigens.
In vitro immune models using exclusively human materials
are desirable to enhance the likelihood of achieving single-
antigen specific responses to xenogenic antigens provided by
vaccines. Efficient protective immunity induced by vaccines
requires a microenvironment where a timely interplay of cellular
and molecular events enable the capture and processing of
rare exogenous antigens by antigen-presenting cells and their
subsequent presentation to rare matching naïve lymphocytes
at neighboring lymphoid tissues (6). Dendritic Cells (DCs) are
the most effective antigen-presenting cells for initiation of T
cell immunity (7) and T cells help is considered essential to
achieve effective antibody responses (5) to antigenic proteins
present in most vaccines. Currently, the use of DCs in human
in vitro immune models largely rely on cumbersome extractions
from tissues or blood, artificial differentiation of monocytes
or circulating stem cell precursors using exogenous cytokines
(e.g., Granulocyte-Macrophage Colony-Stimulating Factor
(GM-CSF) and Interleukin (IL)-4), or the use of immortal
DC-like cell lines (8). In vivo, most resident lymph-homing DCs
develop from blood circulating precursors (e.g., monocytes)
after extravasating inside the tissues (9). This autonomous DC
differentiation process was first observed in vitro by a model of
constitutive transendothelial translocation of human monocytes
(10) and later confirmed in vivo (11); here, DCs traversed the
endothelium in an abluminal-to-luminal direction (reverse
transendothelial migration) resembling the constitutive tissular
egress of dermal DCs en route to the draining lymphatics in
vivo (12, 13). Tissue niches left behind by migratory DCs in
vivo are continuously replenished by monocytes extravasating
from the general circulation through capillaries (14), small
veins consisting of a single-cell endothelium and a basement
membrane or interstitium (15). Thus, the endothelium of
capillary veins is key to the natural development and relative
abundance of tissue-resident monocytes, macrophages (MØ)
and DCs, which first encounter pathogens and vaccines in vivo.
In light of the physiologic events described above, we
took a tissue engineering approach to emulate this natural
microanatomy, physiology, and antigenic footprint of a human
capillary vein. Naturally consisting of a single-cell endothelial
layer and an interstitium, therefore deprived of the cell
complexity, migrations, and interactions pertaining to more
complex tissues in vivo, our tri-dimensional human age-specific
vascular-interstitial interphase model recreated the autonomous
differentiation and migration behavior of DCs, making it suitable
for in vitro vaccination studies. While similar prior tissue models
have demonstrated autonomous generation of human DCs from
extravasating monocytes without the use of cytokines (10, 16–
19), these models lacked two key features that may be important
for accurate age-specific modeling of human vaccine responses:
(1) having an entirely human-derived composition of cells,
matrix and fluid phase, desirable as the presence of non-human
proteins (e.g., xenogenic bovine matrix, endotoxin) in a human
in vitro immune testing model may interfere with desired uptake
and processing of scarce vaccinal antigens needed to study rare
autologous single-antigen specific naïve T cell responses; and
(2) including age-specific primary leukocytes and autologous
plasma to enable ontogenic assessment of vaccine responses, a
key parameter of immunity. A significant novelty of our model
is its focus on being as physiologic as possible (e.g., minimal
cell manipulation, non-heat-treatment of plasma, no exogenous
factors) to maximize the likelihood that in vitro results will
mirror those in vivo thereby enhancing translation. Herein we
report the development of age-specific human tissue constructs
that enabled natural capture of vaccinal antigens by DCs, and
accurate autologous single-antigen specific newborn immune
responses to HBV and BCG vaccines, with comparable antigen-
specific immunogenicity in vitro as observed in vivo. This
microphysiologic human culture platform offers a new approach
to early pre-clinical selection of effective vaccine candidates that
could help accelerate, de-risk, and enhance age-specific vaccine
development.
MATERIALS AND METHODS
Reagents
Adjuvants: Adjuvants studied included Aluminum Hydroxide
(AlOH; at 5 and 50µg/mL), Aluminum Phosphate (AlPO, at 2.5
and 25µg/mL) from Statens Serum Institut (SSI Copenhagen,
Denmark). Toll-Like Receptor (TLR) agonists (TLRAs) including
TLR2/1A Pam3CSK4 (Pam3, at 1 and 10µg/mL), TLR4A 3-O-
desacyl-4′-monophosphoryl lipid A (MPL, at 1 and 10 ng/mL)
and the TLR7/8A imidazoquinoline Resiquimod (R848, at 5
and 50µM), all purchased from InvivoGen (San Diego, CA).
Vaccines: Recombinant Recombivax HB©R (HBV, at 1:100, 1:10
and 1:2v/v dilutions) and PNEUMOVAX©R 23 (PVP, at 1:100
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and 1:10v/v dilutions) were purchased from Merck (Whitehouse
Station, NJ). PREVNAR-13©R (Pneumococcal Conjugate Vaccine
or PCV, at 1:100, 1:10, and 1:2v/v dilutions) was purchased from
Wyeth Pharmaceuticals Inc. (Pfizer subsidiary; Philadelphia,
PA). Pentavalent vaccines given to infants enrolled into the
randomized trial in Bissau, Guinea-Bissau (20) were EasyfiveTM
(Panacea Biotec, India), Quinvaxem©R (Berna Biotech Korea
Corp), or Pentavac©R (Serum Institute of India Pvt. Ltd).
BCG Danish strain 1331 (1:100, 1:20 and 1:10v/v dilutions)
was purchased from SSI (Copenhagen, Denmark). Peptides:
Ag-specific challenges were performed using pools of 50%
overlapping endotoxin-free peptides based on antigens present
in licensed vaccines tested in vitro (Supplementary Table 1).
Peptide’s manufacture was chemical synthesis (Synprosis SA,
Fuveau, France). For BCG studies, 28 peptides, ∼20-monomers
long, encompassing the entire sequence of mycobacterium
antigen Ag85A (21), were ordered. For HBV studies, 15 peptides,
10–18 monomers long, encompassing the entire sequence
of Hepatitis B virus antigen HBsAg (22), were synthesized.
Same number of background control peptides was made using
scrambled sequences unrelated to mycobacteria or Hepatitis
viruses based on the Basic Local Alignment Search Tool
(BLAST©R ) from the US National Library of Medicine of The
National Institutes of Health. Each peptide was individually
solubilized at high concentration in DMSO and stored at
−20◦C, per the manufacturer’s recommendations. Before
testing, individual peptides were combined to prepare peptide
pools stock solutions in plasma-free RPMI media. To remove
any potential microparticles, each peptide stock was filtered
using a low protein binding, non-pyrogenic, sterile 0.2mm
Supor©R membrane filter (PALL Life Sciences Corporation;
Port Washington, NY). Peptide stocks concentrations were
assessed by the Bicinchoninic Acid protein assay kit (Thermo
Scientific Pierce; Rockford, IL). Other reagents: Defined Fetal
Bovine Serum (FBS) was purchased from Hyclone (Logan, UT).
Culture media M199 and RPMI-1640, 1X Hank’s Balanced Salt
Solution (HBSS), 1X Dulbecco’s Phosphate Buffered Solution
without calcium or magnesium (DPBS), 0.25% Trypsin-EDTA
(100X solution), ultrapure 0.5M EDTA, 16% paraformaldehyde
(PFA) solution and 100X Penicillin/Streptomycin/ Glutamine
(PSG) solution were purchased from Gibco©R (Thermo Fisher
Scientific Inc.). Pyrogen-free heparin was purchased from
Sagent Pharmaceuticals©R (Schaumburg, IL). Collagenase
enzyme with no tryptic activity was from Roche Diagnostics.
Sodium hydroxide (NaOH 10M), dimethyl sulphoxide (100%
ACS DMSO, Hybri-Max©R ), Trypan Blue stain (0.2%),
Haematoxylin-Eosin (H&E), and Glucose-6-Phosphate (G-
6-P) were from Sigma-Aldrich (St. Louis, MO). Ficoll-Paque
PREMIUMTM was from GE Healthcare Life Sciences (Pittsburgh,
PA).
Human Materials
Newborn and adult blood: Adult blood (50–300mL) from
healthy study participants (26–45 years old) was collected
via peripheral venipuncture after written informed consent in
accordance with the Declaration of Helsinki and as approved
by the Institutional Review Board (IRB) of Boston Children’s
Hospital (BCH) (protocol number X07-05-0223). HBV and
BCG vaccination history, the most recent mycobacteria Purified
Protein Derivative (PPD) Delayed-type hypersensitivity (DTH)
status and anti-HBsAg-Ab titers, were obtained for most
adult donations. Anti-HBsAg-Ab titers from newborn and
adult plasmas were measured at the BCH Clinical Core
Laboratory using the Abbott Architect i1000 Immunoassay
Analyzer instrument (Abbott Diagnostics, Chicago IL) and their
assay kit (#34-5498/R4). While Recombivax HB©R manufacturer
establishes a correlate of protection of ≥10 mIU/mL (23),
the BCH recommendation of ≥12.0 mIU/mL was followed.
Newborn blood (50–100mL) was collected by venipuncture of
umbilical cords (mean gestational age 38.9 weeks), immediately
after elective Cesarean-section delivery (epidural anesthesia)
of de-identified mothers with no record of fever, HIV
or other acute or chronic infections, following protocols
approved by the local IRBs of The Brigham and Women’s
Hospital (Protocol #2000P000117/BWH) and the Beth Israel
Deaconess Medical Center (Protocol #2011P-000118/BIDMC).
Blood samples were drawn into syringes containing pyrogen-
free heparin (final concentration 20 units/mL) and processed
within 2 h of collection to separate plasma and mononuclear
cells. Heparinized plasma samples from an infant cohort
receiving early vs. delayed BCG: Plasma was obtained
from infants enrolled in a randomized trial in Bissau,
Guinea-Bissau (West Africa; clinicaltrials.gov: NCT00625482)
comparing immunological effects on infants receiving BCG
within the first week of life (early BCG) vs. delayed-BCG
vaccination (Ø) (20). Eligible newborns weighed <2.50 kg, had
no major malformations, had parents who provided informed
consent, and were ready to leave the maternity ward. BCG
vaccine (SSI, Statens Serum Institut, Copenhagen, Denmark) was
normally provided at birth (50 µL, intradermal) for neonates
weighing >2.50 kg, otherwise it was postponed until infants
gained weight, typically at the time of their subsequent scheduled
routine vaccination at 6 weeks of age. Frozen plasmas were
shipped from Bissau by air courier under temperature control
and were used to assess Adenosine Deaminase (ADA)-1 and
ADA2 activities in relation to BCG immunization. Samples
from infants who were randomized at >7 days of life to
early vs. delayed BCG, as well as samples in the delayed
BCG group who had received BCG before donating blood,
were excluded of ADA study. All infants received oral polio
vaccine (OPV) at birth; none had pentavalent DTPw-HepB-
Hib vaccine before 4 weeks of age (recommended at 6,
10, and 14 weeks); most samples studied for ADA activity
were from study participants with 1 dose of pentavalent
vaccine before the 10-week-old blood donation. Isolation and
cryopreservation of autologous plasma and mononuclear
cells: Blood was centrifuged at 1,200 revolutions per minute
(rpm) for 10min at 24◦C to separate plasma and hemocytes.
Plasma was centrifuged again at 3,000 rpm for 30min to
generate platelet-poor plasma and then frozen at −20◦C until
further analysis. Plasma used on studies was never heat-
treated. Hemocytes were resuspended in 1x DPBS with 2%v/v
heparin to regain the original blood volume. Mononuclear Cells
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(MCs) were isolated by Ficoll©R density gradient centrifugation
according to manufacturer’s specifications. Newborn cord blood
MCs and adult peripheral blood MCs were counted (Trypan
Blue exclusion) and cryopreserved at a cell density of 100
million/mL using 1mL of plasma-free cryopreservation media
consisting of 1x DPBS containing 10% DMSO, 44 mg/mL HSA
and 2mM EDTA. MCs were placed inside a pre-cooled (4◦C)
Mr.FrostyTM freezing container (Nalgene ©R , Sigma-Aldrich;
St. Louis, MO) according to manufacturer’s instructions and
rapidly moved to an −80◦C freezer. After over-night storage,
cell amps were transferred to a liquid nitrogen tank for long-
term storage. Extracellular matrix proteins, albumin and
endothelial cells: Human type I collagen solution (VitroCol©R ,
3 mg/mL) was purchased from Advanced BiomatrixTM (San
Diego, CA). Human Fibronectin was purchased from Biomedical
Technologies Inc. (Stoughton, MA). Clinical grade Human
Serum Albumin (HSA) was purchased from Octapharma
(Lachen, Switzerland). A single-donor HUVEC lot, evaluated
for appropriate growth characteristics, was selected for purchase
from LonzaTM (Walkersville, MDUSA) and used across all of our
experiments.
Endotoxin Testing
All human materials and reagents were confirmed to be
endotoxin-free (≤0.2 Endotoxin Units/mL at working
concentration) with a Kinetic Turbidimetric (KTA) LAL
test using the KTA2 reagent and following manufacturer’s
instructions (Charles River Laboratories International,
Inc.; Wilmington, MA). Additionally, some reagents were
tested further to ascertain they were biologically inert
using a standardized whole blood TNF-α release assay at
working concentrations as we have previously described
(24).
Generation of Tissue Constructs
Building from prior tissue engineering efforts (10), our
tridimensional TC model consists of a confluent quiescent
monolayer of single-donor human umbilical vein endothelial
cells (HUVECs) grown over a basement membrane made
of human extracellular matrix proteins using human plasma
(Figure 1 I–III). This in vitro tissue arrangement closely mirrors
both the components and architecture of capillary veins in vivo
(15). Timing: The process of creating TCs spanned 10 days
before the start of a TC assay (e.g., D-12 to D-2), at which
point newborn or adult monocytes were allowed to colonize
TCs and adjuvant or vaccine stimulations were begun (D-2).
Details are described below along this timeline: D-12: Single-
donor HUVECs were cultured at 5% CO2/37
◦C in M199 media
containing 50% FBS and 1% PSG. HUVECs started culture in
75 cm vented cap tissue culture flasks (Corning Life Sciences;
Tewksbury, MA) pre-coated with a 0.5 mg/mL solution of
human fibronectin. Excess fibronectin was removed before the
addition of the HUVECs. D-9: Endotoxin-free human type I
collagen cushions were cast in 96-well microtiter plates (Costar
round bottom, Thermo Fisher Scientific Inc.), as described earlier
(16). Human type I collagen cushion solution was prepared by
mixing 10x M199 media, 0.1N NaOH and the human collagen (3
mg/mL) at a proportion 1:5:8, respectively. Seventy microliters
of this solution was applied to each of the inner 60 wells
of a 96 well flat bottom Falcon©R microtiter plate (Becton
Dickinson; Bedford, MA) using a repeating dispenser, and the
plate incubated at 5% CO2/37
◦C for 24 h. After congealing,
cushions were aged by applying a neutralized (with 10N NaOH;
pH between 6.5 and 7) and filtered (Acrodisc©R unit, at a rate
defined by the manufacturer) solution of G-6-P (225mM in
HBSS). Collagen cushions received 50 µL of G-6-P solution
using a repeating dispenser and then incubated at 5% CO2/37
◦C
for an additional five days. Meanwhile, using Trypsin-EDTA
and the same M199 media containing 50% FBS and 1% PSG,
the 85–90% confluent HUVEC cultures (as assessed with an
inverted microscope) were passed to larger (150 cm) vented
cap tissue culture flasks pre-coated with human fibronectin (0.5
mg/mL) and incubated at 5% CO2/37
◦C. D-4: Four days before
the assay, G-6-P solution was removed out of every cushion
by aspiration, 200 µL of HBSS were added to each well of
the 96-well plate (including the 36 empty wells around the
60 inner wells with cushions, as an evaporation barrier) prior
to returning the plate to the 5% CO2/37
◦C incubator. D-3:
HUVEC cultures were enzymatically harvested with Trypsin-
EDTA, washed twice with 1x DPBS to remove any potential
trace of residual FBS and resuspended in fresh M199 media
containing 1% PSG and 30% human newborn pooled plasma
(previously prepared using small volume leftover plasmas from
several study participants). Cells from one confluent T150 flask
were resuspended in ∼13mL of media to be dispensed as 100
µL per well (120 wells). Ten minutes before seeding endothelial
cells, collagen cushions were prepared by aspirating out the
HBSS and adding 20 µL of 0.5 mg/mL human fibronectin.
Typically, one T150 flask of confluent HUVECs contained
sufficient cells to coat two cushion plates (180 wells).Assessment
of TCS at D-2 before starting an assay: Monolayer integrity,
confluence, and cobblestone morphology of endothelial cells
was assessed by inverted microscopy using phase contrast at
4x magnification (Nikon TS100 inverted microscope, Nikon
Instruments Inc.; Melville, NY). Only 100%-confluent TCs were
used for testing.
Generation of Age-Specific Human Tissue
Constructs
Age-specificity of TCs was achieved by allowing monocytes
from either a newborn or an adult participant to autonomously
extravasate inside the TCs and removing non-migrated
monocytes after 1.5 h of incubation. Every assay compared
responses between one newborn and one adult. Monocytes were
positively selected from freshly thawed MCs using magnetic
micro-beads covalently linked to anti-CD33 mAbs (MACS©R
positive selection, Miltenyi; Cambridge, MA). CD33 rather
than CD14 was chosen in order to: (a) avoid interference with
important antigen-capture molecules (25); (b), avoid induction
of non-physiological activation (26); and (c), provide more
natural monocyte heterogeneity (27). ∼105 monocytes were
applied to each TC well and allowed to autonomously extravasate
under static conditions for 1.5 h in serum-free M199 media
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FIGURE 1 | The Tissue Construct (TC) model. Single donor human endothelial cells (I, representative image, 20X) were grown onto cast cushions of human collagen
(II) and cultured with human plasma media until reaching quiescent confluency (III, representative image, 4X). Age-specific TCs were created by allowing CD33+
selected newborn or adult monocytes (IV, representative dot plots) to colonize the quiescent confluent TCs. After removal of non-extravasated monocytes (V),
age-specific TCs were cultured for 48 h in autologous non-heated plasma +/− adjuvants or vaccines to allow for autonomous dendritic cell (DC) development,
maturation and reverse transendothelial migration (V-VII). Age-specific DCs, autonomously developed from TCs stimulated with pediatric vaccines, were co-cultured
with autologous untouched naïve CD4+ CD45RA+ T cells (VIII, representative dot plot) and autologous non-heated plasma for seven to 31 days (IX, D7 … D31), as
described in methods. Mature (red) and immature (blue) DCs from TCs as defined by the co-expressions levels of HLA-DR and CD86 markers (representative dot
plots of initially extravasated monocytes extracted from TCs at 0 h and autologous DCs harvested 48 h later after stimulation). Representative images of co-cultures at
Day 0 (D0) and D7 (10X, scale bars = 200µm). Blue arrow indicates monocytes inside TCs (H&E staining, representative image, 20X). Black arrow indicates DCs
accumulated on top of endothelium (phase contrast, representative image, 20X). Scale bars = ∼200µm. I, Isotype controls.
containing 1% PSG and 0.1% HSA at 37◦C/5%CO2. After this,
non-migrated monocytes were removed by gentle aspiration
and several consecutive washes with warm 1x DPBS and
monocyte-colonized TCs were ready for testing (Figure 1 IV–V).
Of note, non-extravasated monocytes do not become DCs after
being on the endothelium for 1.5 h, and monocytes that do not
reverse transmigrate after 48 h of culture, remain inside TCs
as macrophages independently of stimulation (10). To assess
monocyte extravasation, TCs were fixed with fresh 10% PFA,
stained with H&E and examined with an inverted microscope.
Assessment of Autonomous DC
Development From Age-Specific Tissue
Constructs
To enable autonomous generation of age-specific DCs,
monocyte-colonized newborn TCs (NTCs) and adult TCs
(ATCs) were cultured for 48 h with innate immune stimuli in
autologous plasma (Figure 1 VI), a natural source of age-specific
immunomodulatory factors (2, 28). After this time, about half
of the initially extravasated monocytes become either immature
or mature DCs, depending on the type and degree of adjuvant
or vaccine stimulation added at step VI, transmigrating back
out of the extracellular matrix and across the endothelial layer,
in a step that mirrors movement of tissue antigen-presenting
cells from tissue sites to the lymphatic system (12, 13). As
previously described (10), the only location where TC culture
conditions demonstrate high percentage of mature DCs is
amongst stimulated reverse transmigrated cells (VII). When TCs
are left unstimulated (e.g., vehicle control), reverse transmigrated
cells accumulate on the luminal side of the endothelial monolayer
at same degree than stimulated TCs but demonstrating very low
relative DC maturation. Thus, as with capillary veins in vivo, the
endothelium of our model is key to the natural development and
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relative abundance of tissue-resident macrophages andmigratory
DCs. For practical purposes, since reverse transmigrated cells
are a mix of immature and mature DCs, all harvested reverse
transmigrated cells will be referred generally as DCs (e.g.,
DC:T cell co-cultures). Timing: The process of stimulating
TCs spanned 2 days. Details are described below along this
timeline: D-2: age-specific (monocyte-colonized) TCs were
cultured for 48 h at 37◦C/5% CO2 in the presence of 100 µL of
autologous non-heated plasma, with no additional exogenous
cytokines, with or without adjuvants, licensed vaccines or
desired controls. Some experiments included conditions in
which autologous plasma from the newborn and the adult were
swapped to assess the relevance of using autologous plasma, as
compared to homologous (adult-newborn swap) or xenogenic
(Fetal Bovine Serum). Unstimulated control (Ø) TCs received a
volume of sterile aqueous carrier solution equal to corresponding
stimulator tested or, when several doses tested, corresponding
to the highest concentration tested for that stimulator. In this
model, during the 48 h stimulation, monocytes autonomously
differentiate into migratory DCs that reverse transmigrate out
of TCs, crossing the endothelium in abluminal-to-luminal
direction (Reverse Transendothelial migration) to accumulate
on the luminal side of the endothelium. D0: typically, DCs from
5 to 20 TC replicas/condition were collected by gentle pipetting
in warm 1x DPBS and counted with vital staining Trypan
Blue following manufacturer’s recommendations. Phenotypic
analysis of DCs by flow cytometry: Autonomous development
and maturation of DCs from unstimulated and stimulated
age-specific TCs (Figure 1 VII and Supplementary Videos 1–3)
was investigated using polychromatic flow cytometry. This
technique was also used to assess purity of cell selections.
Immunophenotyping used direct-conjugated monoclonal
antibodies (mAbs) against CD33-PE, CD14-APC, CD86-PE,
HLA-DR-FITC, and CD197-BV421 (Becton Dickinson; Franklin
Lakes, New Jersey). Cells were stained for 30min with mAbs
as recommended by manufacturer, rinsed with DPBS and fixed
with freshly made 4% PFA solution. Corresponding direct
conjugated isotype mAbs and unstained controls were used to
determine non-specific binding. Flow cytometry employed a BD
LSR-FortessaTM (Becton Dickinson) and data analyzed using
FlowJo©R software (Tree Star, Inc.; Ashland, OR) using a single
viable gate. To compare the phenotype of cells inside TCs at D-2
with corresponding cells at D0 for a given study participant, cells
were retrieved from inside TCs using tryptic-free collagenase
digestion, according to manufacturer’s recommendations.
Video-microscopy of cells inside TCs: A trans-perpendicular
video of the Tissue Construct after 48 h of culture was generated
using series of pictures taken approximately every 20µm
from the top of TCs, moving down (Supplementary Video 1).
For this, TCs were fixed with fresh 10% PFA after removal
of reverse transmigrated DCs from the luminal side of the
endothelium, stained with H&E and then examined with an
inverted microscope. A time-lapse video of live monocytes at
∼50µm inside an un-fixed Tissue Construct after 18 h of culture,
was generated with pictures taken with the microscope every
30 s for a time span of about 15min and compressed in ∼8 s
(Supplementary Video 2). A time-lapse video of live Dendritic
Cells projecting dendrites (sampling) at ∼50µm inside an
un-fixed Tissue Construct after 24 h of culture, was made with
pictures taken every ∼15 s for a time span of about 10min and
compressed in∼15 s (Supplementary Video 3).Analysis of DCs
using confocal microscopy: Confocal microscopy was employed
to assess changes in morphology and surface translocation
of HLA-DR on DCs stimulated with HBV (1:2v/v) or BCG
(1:20v/v). DCs were harvested and transferred to a 24-well
flat-bottom tissue-culture plate (Falcon, Becton Dickinson) with
BD BioCoatTM round Poly-L-Lysine Coated Glass Coverslips
(two 12-mm diameter coverslips per condition) with autologous
plasma to continue incubation at 37◦C/5% CO2 for 1 h and
regain natural cell morphology. Coverslips were washed once
with warm 1X DPBS and then fixed and permeabilized with BD
Citofix/CytopermtTM (Becton Dickinson). After another wash
with BDWashing Buffer, cells were stained with HLA-DR-FITC,
DNA dye DraQ5tTM (eBiosciences, Inc.; San Diego, CA) and
Alexa Fluor©R 594 phalloidin F-actin (Molecular Probes, Inc.;
Eugene, OR) in 1x DPBS with 0.5% HSA for 30 min/37◦C/dark.
Corresponding isotype mAbs served as controls for non-specific
background fluorescence. Coverslips were mounted with 50%
glycerol in DPBS and sealed with transparent non-florescent nail
polish (Thermo Fisher Scientific Inc.). Images were acquired
using Slidebook©R software on an Axiovert©R 200m fluorescent
microscope (Zeiss; Thornwood, NY), with a 63X Immersion
Objective. Slidebook©R features allowed for the reconstruction
of three-dimensional rotational-ax confocal video-microscopy
using acquired stacked pictures (Supplementary Video 4). Also,
plane-by-plane confocal video-microscopy reconstructions were
made using acquired confocal images taken at focal planes
0.2µm apart (Supplementary Videos 5, 6). To assess uptake
of BCG (M. bovis), mycobacteria were labeled with DraQ5TM
dye for DNA and lipophilic dye 1,1’-Dioctadecyl-3,3,3’,3’-
Tetramethylindocarbocyanine Perchlorate (DiI or DiIC18)
for bacterial membrane lipids, as previously described (29),
prior to addition to TCs. 0.25µm thick optic focal plane cuts
were imaged to verify intracellular presence of bacteria. ADA
activity in plasma after immune stimulation of age-specific
TCs: ADA1 activity was measured in age-specific supernatants
(D0) from BCG in vitro immunized TCs. This technique was
also used to determine ADA1 and ADA2 activities in untreated
plasma samples from the newborns and adults recruited for
our in vitro studies, directly after separation from blood, and
from plasma samples obtained by a Guinea-Bissau clinical trial
comparing birth-BCG vs. delayed-BCG scheduled. ADA1 and
ADA2 activities in plasma (Units/Liter) were determined with a
chromogenic assay kit (Diazyme Laboratories, Inc.; Poway, CA),
in 384-well plates, using recommended controls and calibrator
sets and maintaining reagent ratios, as per manufacturer’s
recommendations. Assay was run in duplicate with or without
ADA1 inhibitor erythro-9-(2-Hydroxy-3-nonyl)-adenine
hydrochloride (EHNA, 20µM). Since ADA2 is not EHNA
sensitive, ADA2 activity is determined by EHNA-containing
wells. Results were read on a Tecan Infinite 200 and ADA1
activity was calculated by subtracting ADA2 activity from total
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ADA activity, as recommended by the manufacturer. One unit of
ADA is defined as the amount of ADA that generates one µmole
of inosine from adenosine per min at 37◦C.
Stimulation of Autologous Lymphocytes by
DCs From in vitro Vaccinated Tissue
Constructs
The stimulatory capacity of autonomous TC-derived DCs toward
autologous untouched CD4+ T cells (Figure 1 VIII–IX) was
investigated by measuring proliferation and cytokine production
after several days of co-culture in the presence of 10% autologous
plasma, with no media changes or the addition of exogenous
factors. Timing: Age-specific TCs were prepared and pulsed
(D-2) with licensed pediatric vaccines (e.g., HBV, PCV, PVP,
or BCG), as previously described. Two days later (D0) DCs
were harvested and co-cultured for up to seven days with
either autologous naïve CD4+ CD45RA+ T cells to assess
their capacity to initiate primary responses or with autologous
total CD4+ T cells from recruited study participants with
positive BCG and/or HBV vaccination history, in order to assess
the capacity of our model to detect or re-stimulate memory
responses. Untouched CD4+CD45RA+ naïve T cells and CD4+
pan T cells were isolated by negative selection from freshly
thawed MCs using magnetic microbeads (MACS©R isolation kit,
Miltenyi Biotech GmbH; Bergisch Gladbach, FRG), following the
manufacturer’s instructions. Lymphocytes were routinely >98%
pure, as assessed by multicolor flow cytometry with mAbs CD4-
PE, CD3-APC, and CD45RA-FITC (Becton Dickinson; Franklin
Lakes, New Jersey). DC:T cell co-cultures were setup in 96-
well microtiter plates at ratio 1:10 (5 × 103 DCs + 5 ×
104 T cells) in 200 µL of RPMI1640 Media containing 10%
autologous plasma and cultured at 37◦C/5% CO2 with no media
changes. Analysis of autologous lymphoproliferation induced
by DCs from in vitro vaccinated TCs: Lymphoproliferation
was assessed by the H3-thymidine incorporation method at
various time-points (D3, D5 andD7). Eight hours before analysis,
a sample of media was collected and stored at −20◦C for
cytokine assessment and then, 1 µCi/well of H3-Thymidine
(PerkinElmer; Waltham, MA) was added to each culture well,
including some empty background controls. The whole 96-
well-plate with co-cultures were harvested into glass fiber filter
mats (PerkinElmer) using a Harvester96 (TomTec; Hamden,
CT) and read with a 1450 Microbeta Counter (PerkinElmer).
Depending on cell availability, 3 to 14 DC:T cell culture replicas
were setup per condition, leaving rows of empty wells in
between conditions. Other background controls tested included:
unstimulated cultures, naïve T cells that were co-cultured with
DCs, naïve T cells co-cultured with live attenuated BCG but
no DCs and BCG vaccine alone in regular media with no
antibiotics. Counts Per Minute (CPM) were calculated as the
mean of all replica co-cultures per harvested condition for
each donor. Cytokines released after immune stimulation of
autologous lymphocytes by DCs from in vitro vaccinated TCs:
Supernatants from DC:T cell co-cultures at D3, D5, and D7
were harvested and stored at −20◦C until use. Cytokines were
measured after a single freeze-thaw cycle by a fluorometric
bead-based array method, using human 17-, 26-, or 29-
plex Cytokine/Chemokine panel kits (Millipore; Billerica, MA)
and a Luminex Multiplex Instrument (Millipore), following
manufacturer’s recommendations. This technique was also used
to measure cytokines released in cultures after an Ag85A-specific
peptide challenge. Panel of analytes included IL-1ra, IL-1α, IL-1β,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-12p40,
IL-12p70, IL-13, IL-15, IL-17, TNF-α, TNF-β, IFN-α2, IFN-γ,
IP-10, CCL2, G-CSF, GM-CSF, MIP-1α, MIP-1β, EGF, Eotaxin
(CCL11), and VEGF.
Autologous Ag85A-Specific Lymphocyte
Challenge Responses Induced by BCG in
vitro Immunization
Timing: Age-specific TCs were prepared and pulsed with
licensed pediatric vaccine BCG or left unstimulated, as previously
described. At D0, DCs were harvested and co-cultured with
autologous naïve CD4+ CD45RA+ naïve T cells for up to
15 days. As before, all DC:T cell co-cultures were setup in
96-well microtiter plates at ratio 1:10 (5 × 103 DCs + 5
× 104 T cells) in 200 µL of RPMI1640 Media containing
10% autologous plasma, with no media changes. D15: Resting
T cells were harvested, washed, counted and re-plated (5 ×
103 cells/well) in 10% autologous plasma media to undergo
further culture-challenge with 5× 104 freshly selected autologous
CD33+ monocytes (10:1 monocyte:T cell ratio) and a pool
of peptides encompassing the entire sequence of mycobacteria
antigen Ag85A. Peptides and monocytes were not pre-incubated
and no media changes or additives were provided during culture.
D20, D22 andD25: At days 20, 22, and 25, cells and supernatants
were analyzed for proliferation and cytokines, respectively.
Autologous Ag85A-challenge lymphoproliferation induced by
in vitro immunization with BCG: Split T cells (D15) were
either challenged with a pool of 28 Ag85A peptides (Ag-specific,
560µg/mL) or with a pool of 28 corresponding scrambled
sequences (background control, 560µg/mL). Single-peptide final
test concentration was ∼20µg/mL. Other specificity controls
included were split T cells with no challenge, split T cells
challenged with peptides but no monocytes and Ag-specific
challenged autologous naïve T cells never exposed to DCs
from BCG-stimulated TCs. Lymphoproliferation in response
to challenges was assessed by the H3-thymidine incorporation
method at D20, D22, and D25, with as many replica wells
per condition as possible, as previously described. Cytokines
induced by Ag85A-challenge after BCG in vitro immunization:
Supernatants fromD25 were harvested and stored at−20◦C until
use. Cytokines were analyzed bymultiplex cytokine bead array, as
previously described.
Autologous HBsAg-Specific Lymphocyte
Challenge Responses Induced by HBV in
vitro Immunization
Timing: Age-specific TCs were prepared and pulsed (D-2) with
licensed pediatric vaccine HBV (1:100v/v dilution), as previously
described. At D0, DCs were harvested and co-cultured at
37◦C/5% CO2 with autologous total CD4+ T cells in 96-well
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microtiter plates at ratio 1:10 (5 × 103 DCs + 5 × 104 T cells)
in 200 µL of RPMI-1640 Media containing 10% autologous
plasma. To model the second immunization of HBV, as given
in vivo, a second set of age-specific TCs was started at D5,
using autologous monocytes from same two participants used
at D-2. These new TCs were vaccinated in vitro with same
lot and dose of HBV (1:100v/v), but now using two kinds of
plasmas: (a) autologous plasma; and (b), half autologous plasma
mixed with half plasma from the opposite age-group participant
being tested on that same assay (1:1v/v mix of plasmas). At
D7, half of media (100 µL) of the ongoing DC:T cell co-
culture was removed by gentle aspiration to provide room for
the second round of autologous HBV-stimulated DCs (Boost).
Boosting DCs were harvested from the new set of TCs and
supplied to ongoing co-cultures in 100 µL of corresponding 10%
autologous plasma media or 10% plasma from the opposite age-
group participant being tested on that same assay; such that,
when combined with remaining autologous co-culture media
produced a final 10% of 1:1v/v mixed plasmas. Thus, from D7
onward for each age-group participant on that assay half the
boost DC:T cell co-cultures will have autologous plasma and the
other half will have mixed plasma. At D21, resting T cells were
harvested, washed, counted, and re-plated (5 × 103 cells/well) in
corresponding plasma media (same as used at D7) to undergo
further culture (CHALLENGE) with 5 × 104 freshly selected
autologous CD33+ monocytes (10:1 monocyte:T cell ratio) and
a pool of peptides encompassing the entire sequence of HBV
antigen HBsAg. Peptides and monocytes were not pre-incubated.
At D31 selected samples were analyzed for proliferation and T
cell Receptor (TCR) sequencing. Autologous HBsAg-challenge
lymphoproliferation by HBV in vitro immunization: Split
T cells (D21) from each age-group participant were either
challenged with a pool of 15HBsAg peptides (300µg/mL) or with
a pool of 15 corresponding scrambled sequences (background
control, 300µg/mL). Single-peptide final test concentration
was ∼20µg/mL. Lymphoproliferation in response to challenges
was assessed by the H3-thymidine incorporation method at
D31, with as many replica wells per condition as possible, as
previously described. All adult blood used for these experiments
was from participants with positive HBV vaccination history.
Plasma HBsAg-Ab titers were investigated after conclusion of the
study (Supplementary Table 2). Inter-assay peptide-challenge
proliferation reproducibility was retrospectively investigated
after realizing the unplanned re-usage of blood from 3
adult participants; these donations occurred with >1 year
span in between them (Supplementary Figure 1). HBsAg-
challenge expansion of T cell clones associated to HBV
in vitro immunization: Cells from three HBsAg-challenge
experiments, each containing one newborn tested side-by-side
to one adult, were taken from seven time-points/conditions
detailed at design schematics (Figure 6A, indicated as ©1 ,
©2 , ©3 , ©4 , ©5 , ©6 , and ©7 ). Fast-frozen cell pellets were
shipped to Adaptive Biotechnologies©R Inc. (Seattle, WA) where
genomic DNA was prepared using the Qiagen©R DNeasy
Blood & Tissue Kit (Germantown, MD), according to the
manufacturer’s instructions. Samples were quantified using
Dropsense96 (TRINEAN NV; Gentbrugge, Belgium), diluted in
buffer to a standard concentration for library preparation prior
to high-throughput sequencing of the TCRβ complementarity-
determining region 3 (CDR3). Sequences were amplified from
genomic DNA using a two-step, bias-controlled multiplex PCR
approach (30). First PCR amplified the hypervariable CDR3
of the immune receptor locus using forward and reverse
amplification primers specific for every V and J gene segments.
Then, a second PCR added “proprietary barcode” and “Illumina
adapter” sequences (Illumina©R , Inc.; San Diego, CA). CDR3
libraries were sequenced on an Illumina instrument according
to the manufacturer’s instructions. Raw sequence reads were
demultiplexed according to Adaptive’s proprietary barcode
sequences. Demultiplexed reads were then further processed
to: (a) remove adapter and primer sequences; (b), identify
and correct for technical errors introduced through PCR and
sequencing; and (c), remove primer dimer, germline and other
contaminant sequences. Data was filtered and clustered using the
relative frequency ratio between similar clones and a modified
nearest-neighbor algorithm, to merge closely related sequences.
The resulting sequences were sufficient to enable annotation
of the V(N)D(N)J genes, constituting each unique CDR3, and
the predicted translation of the encoded CDR3 amino acid
sequences. V, D and J gene definitions were based on annotation
in accordance with the ImMunoGeneTics (IMGT) database.
All rearrangements having an in-frame V and J gene within
the CDR3 region (e.g., relative to the conserved cysteine and
phenylalanine, respectively), and containing no stop codons,
were considered productive, i.e., capable of being part of a
functional antigen-recognition pocket region of a TCR. The
set of observed biological 87 nucleotides long TCRβ CDR3
sequences were normalized to correct for residual multiplex
PCR amplification bias and quantified against a set of synthetic
TCRβ CDR3 sequence analogs (30). The number and frequency
of productive rearranged nucleotide TCR sequences for each
condition and donor, each one likely reflecting a single-donor
T cell with a functional TCR, was formatted and exported for
further analysis using the ImmunoSEQ©R Analyzer (Adaptive
Biotechnologies; Seattle, WA). The sum of frequencies of
productively rearranged non-shared TCRs from each peptide-
challenge sample at D31 (©3 , ©4 , ©6 , and ©7 ), that were also
detected at corresponding D21 HBV PRIME-BOOST sample
(©2 or ©5 ), were plotted side-by-side to evaluate if viable HBV
stimulated (D0) T cell clones had been preferentially maintained
(survival) or numerically increased by HBsAg-specific challenge
(HBV-associated TCRs) after 31 days of culture.
Statistical Analysis
Typically, each assay had a pair of age-specific study participants
(one newborn and one adult), tested side-by-side on each
condition. P ≤ 0.05 were considered statistically significant
and typically denoted as ∗ < 0.05, ∗∗ < 0.01, and ∗∗∗ <
0.001. Results reported are the mean of multiple technical
replicates. Unless otherwise stated, descriptive statistics are
reported as the mean of results produced by each study
participant age group± standard deviation. Paired and Unpaired
T-tests were employed to compare matched observations (e.g.,
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conditions and time-points) and different participants (e.g., age
groups), respectively. For the Ag85A-specific challenge, counts
per minute (CPMs) from D20,–22, and –25 of assay were
normalized by subtracting nonspecific proliferation fromAg85A-
corresponding scrambled sequence peptides, log-transformed
to achieve normality (Kolmogorov-Smirnov test) and then the
parametric paired t-test, two-tailed, was applied to compare
Ag85A-specific vs. scrambled peptides. For Stimulation Index
(SI) assays, one-sample paired T-test against the hypothetical
value of 1.00 was used to compare normalized data (GraphPad
Prism 4 software, GraphPad Software Inc.). For analysis of
ADA activity in plasma from Guinea-Bissau randomized trial,
a sensitivity analysis using linear regression was additionally
performed to control for any potential effect of birth weight
(Stata12, StataCorp, TX, USA). TCR analysis was performed
on three HBV experiments (non-consanguineous newborns and
adults; N = 3 per group) each with seven different time
points/conditions. As all TCs for HBV experiments used the same
primary single-donor HUVECs that could potentially represent a
carry-over contaminant to DC:T cell co-cultures, we sequenced
a sample of untreated HUVECs to validate and control TCR
analysis. TCR sequences, with their relative frequencies, from
the 43 samples (42 test samples plus 1 control HUVEC sample)
were exported using the ImmunoSEQ©R Analyzer tool (Adaptive
Biotechnologies; Seattle, WA). No endothelial TCR sequences
were detected among the 164,738 productive rearranged TCR
sequences generated by the 42 test samples. Test conditions from
non-consanguineous participants were pooled per age group
(newborns and adults; N = 3). To study the relationship between
the T cells resulting from the HBV in vitro immunization
process (D21) and those resulting from the Ag-challenge (D31),
productive re-arranged TCR sequences from samples ©2 and ©5
(D21) were located at samples©3 ,©4 ,©6 , and©7 (D31). Statistical
analyses of TCR numbers and frequencies were performed
for these four resulting datasets (©2 -©3 , ©2 -©4 , ©5 -©6 , and ©5 -
©7 ) for each age group. Only mutually exclusive TCRs, not
overlapping between peptide types in a given plasma condition,
were analyzed. As datasets were not normally distributed, P
values were calculated as the minimum value of two non-
parametric tests (Mann-Whitney U test and One-sample sign
test, one-sided). Paired observations were used when comparing
conditions from the same study participant.
RESULTS
Autonomous Generation of Age-Specific
Tissue Construct-Derived Mature DCs in
Response to Vaccines
Reverse transmigrated leukocyte fractions from NTCs and ATCs
stimulated with low-to-high sublethal concentrations of five
well-known hydrosoluble adjuvants and two licensed newborn
vaccines were analyzed by flow cytometry for the presence of
mature DCs. Conventional surface phenotype of mature human
DCs (9) includes the co-expression of high levels of antigen-
presenting molecule HLA-DR and costimulatory molecule CD86
(Figure 1 VII), de novo expression of mature DC marker
CD197 (formerly CCR7), and negligible levels of monocyte
marker CD14 (HLA-DRhi/CD86hi/CD197+/CD14lo/−). Relative
percentages of viable mature DC events (Figures 2A,B), as well as
surface expression levels (Mean Fluorescent Intensities) for these
markers (Supplementary Figure 2), were analyzed for adjuvants
such as Alum, either as hydroxide (Al-OH) or as Phosphate (Al-
PO), TLRAs including bacterial lipopeptide Pam3CSK4 (Pam3;
TLR1/2A), Monophosphoryl Lipid A (MPLA; TLR4A), and
resiquimod (R848; TLR7/8A), as well as the licensed vaccines
HBV and BCG. Viability of reverse transmigrated cells from
stimulated TCs was not significantly different between age
groups, with means ranging 73.6–84.83% in NTCs and 83.8–
92.6% in ATCs. Reverse transmigrated cells from unstimulated
TCs from both age groups showed higher surface expression
of CD86 and HLA-DR than initially extravasated autologous
monocytes, reflecting on their autonomous differentiation into
immature DCs (10). DC maturation is only achieved after
efficient immune stimulation. Of note, the number of mature
DCs was typically higher in adults than newborns in response
to most adjuvants and BCG vaccine. Consistent with the known
ontogeny of human neonatal leukocytes in responding weakly to
certain adjuvants, and reflecting on inhibitory newborn plasma
factors, including adenosine (2, 31), of all stimuli tested only
R848 and BCG vaccine induced mature DCs from NTCs. To
assess the microphysiological relevance of culturing cells in
autologous plasma (Figure 2B and Supplementary Figure 2), we
compared DC maturation in response to the relatively weak
activator of human neonatal leukocytes TLR2A Pam3 and the
robust activator TLR7/8A R848 (32), as well as HBV and
BCG vaccines, under different plasma conditions. Consistent
with previously reported immunosuppressive effects of neonatal
plasma toward TLR-mediated pro-inflammatory signaling in
whole blood cultures, especially toward TLR2As (24), the TLR2A
Pam3 was less active in the presence of autologous intact
newborn plasma, while substitution with adult plasma enhanced
adjuvant-induced maturation of newborn DCs, especially in
response to Pam3. In contrast, newborn plasma suppressed
stimulus-induced maturation of adult DCs. Consistently, Fetal
Bovine Serum (FBS) limited the Pam3 response of adult cells
similar to the effect of human newborn plasma. Confocal
microscopy of reverse transmigrated cells from BCG-stimulated
TCs (Figure 2C and Supplementary Videos 4–6) demonstrated
a classic DC morphology and maturation as indicated by surface
translocation of HLA-DR molecules (green), initially stored in
Class-II vesicles of immature DCs (33). Internalization of BCG
M. bovis by newborn and adult reverse transmigrated cells
(Supplementary Figure 3) induced a nearly homogeneous DC
maturation (Figure 2C), while in contrast the alum-based HBV
generated a polarized mix of mature and immature DCs.
DCs From Vaccine-Pulsed Tissue
Constructs Induce Autologous CD4+ T
Cell Responses
The ability of BCG vaccine to induce apparently effective
mature DCs from NTCs was consistent with its efficacy
in vivo (2) and enabled us to investigate autologous adaptive
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FIGURE 2 | Tissue constructs enable age- and stimulus-specific generation of autonomously generated newborn and adult DCs by adjuvants and licensed vaccines.
(A) Age-specific maturation of autonomously generated DCs after adjuvant stimulation of TCs. Percentage of viable mature DCs (HLA-DRhi/CD86hi/CD197+/
CD14lo/−) from age-specific TCs stimulated with vaccinal adjuvants: Aluminum hydroxide (AlOH, at 2.5 and 25µg/mL), Aluminum Phosphate (AlPO, at 2.5 and
25µg/mL), Pam3CSK4 (Pam3, at 1 and 10µg/mL), 3-O-desacyl-4
′-monophosphoryl lipid A (MPLA, at 1ng/mL and 10ng/mL) and Resiquimod (R848, at 5µM and
50µM). Triangles indicate low to high concentration. Black stars compared every condition to unstimulated autologous plasma controls, per age group. Green stars
compared age groups for same test and condition. N = 3-10 donors per age group with ≥7 technical replicas per condition. (B) Age-specific maturation of
autonomously generated DCs after vaccine and plasma type stimulation of TCs. Percentage of viable mature DCs (HLA-DRhi/CD86hi/CD197+/CD14lo/−) from
age-specific TCs stimulated by weak newborn stimulus Pam3 (10µg/mL), robust newborn stimulus R848 (50µM) and HBV (1:10v/v and 1:2v/v dilutions) and BCG
(1:20v/v and 1:10v/v dilutions) vaccines. Triangles indicate low to high concentration. Each experiment included conditions in which autologous plasma from the
newborn and the adult were swapped, as described in Methods. FBS was only tested for Pam3. Red stars compared every condition to unstimulated control (Ø), per
plasma type group; black stars compared every condition to unstimulated autologous plasma controls, per age group; blue stars compared the effect of plasma type
on each condition, per age group. N = 3-10 donors per age group with ≥7 technical replicas per condition. (C) Surface translocation of cytoplasmic HLA-DR on
autonomously generated DCs after HBV or BCG vaccine stimulation of age-specific TCs. Cytoplasmic stored HLA-DR class II molecules are seen in green, F-actin
filaments (cytoskeleton) in red and DNA in blue (representative Confocal-microscopy images, scale bar = 10µm). P = * < 0.05; ** < 0.01; *** < 0.001.
responses in vitro. Thus, we focused our attention on modeling
the type of lymphocyte responses induced by this vaccine
in vivo where a single neonatal dose of BCG induces T-cell
proliferation and cytokines (2). Indeed, CD4+ T cells play an
important role in host defense against Mycobacteria spp., as
evidenced by susceptibility of patients with HIV or primary
immunodeficiencies such as SCID or IL-12- or IFN-γ-deficiency
(34, 35). Accordingly, we evaluated the functional capacity of age-
specific TC-derived DCs (reverse transmigrated cells) to induce
proliferation of naïve untouched autologous T helper cells. DCs
from BCG-stimulated TCs were harvested and co-cultured with
autologous CD3+/CD4+/CD45RA+ T cells (36) to measure
proliferation (Figure 3A), as described in Methods. Alum-
adjuvanted vaccines HBV and PCV, previously studied in human
newborns in vivo (37), were also tested in parallel, as reference.
Our approach was to co-culture TC-derived DCs and T cells
under autologous plasma for 7–15 days without media changes
to avoid disrupting naturally formed cytokine microgradients
(38). Purified CD33+ monocytes enabled the harvest of pure
myeloid DCs and a fixed DC:T cell co-stimulation ratio enabled
direct functional comparison between age groups and conditions.
To test in vitro concentrations matching the relative vaccine
antigen/adjuvant contribution of a single newborn dose in vivo,
as above, HBV and PCV (in vivo dose of 500 µL each) were
tested initially at dilution 1:2 v/v, while BCG vaccine was tested
at dilution 1:20 v/v (in vivo dose of 50 µL each). Consistent with
DC maturation results, only DCs from BCG-pulsed NTCs and
ATCs stimulated significant proliferation of autologous naïve T
cells at Day 7 (D7) of culture. BCG results were confirmed with
a seven-day time-course proliferation with background controls
including unstimulated cultures, naïve T cells alone (no DCs),
naïve T cells plus live attenuated BCG (no DCs), and BCG
vaccine alone with no antibiotics (Supplementary Figure 4).
We next characterized vaccine-induced production of Th-
polarizing cytokines in supernatants from previous co-cultures
(Supplementary Table 3). Paralleling lymphoproliferation, adult
co-cultures vaccinated in vitro with BCG produced significantly
higher concentrations of IL-1α, IL-6, IL-7, CXCL8, TNF-
β, IFN-γ, and GM-CSF in response to BCG vs. matched
unstimulated controls. Newborn BCG co-cultures produced an
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FIGURE 3 | Autonomously derived DCs from tissue constructs pulsed with licensed pediatric vaccines induce autologous age-specific T cell proliferation.
(A) Autologous naïve T cell proliferation induced by DCs autonomously generated from age-specific TCs stimulated with pediatric vaccines HBV, PCV, and BCG.
Proliferation of Naïve CD4+ CD45RA+ T cells (Counts Per Minute or CPM) was assessed at day 7 (D7). BCG was used at 1:20v/v dilution; HBV and PCV were tested
at 1:2v/v dilution. N = 5–7 participants/age group, per condition. Black stars compared vaccines vs. unstimulated controls (Ø) on same age group. (B) Autologous
total T cell proliferation induced by DCs autonomously generated from age-specific TCs stimulated with pediatric vaccines PVP, HBV, PCV, and BCG.
Lymphoproliferation (CPM) was assessed at day 7 (D7). T cells were total CD4+. PVP, HBV, PCV and BCG vaccines were tested at equal concentrations. Triangles
indicate low (1:100v/v) and high (1:10v/v) test concentrations. N = 3–9 donors per age group per condition, with ≥7 technical replicas per data point. Recruited adults
had positive history of BCG and HBV vaccinations. Black stars compared vaccines vs. unstimulated controls (Ø) on same age group; green stars compared same
condition between age groups. (C) Cognate lymphoproliferation induced by BCG in vitro immunization. Proliferation of CD4+ T cells (CPM) induced by autologous
DCs from age-specific TCs stimulated with BCG (1:100v/v and 1:10v/v dilutions) was assessed at days 3, 5, and 7. Recruited adults had positive history of BCG
immunization and recent DTH assessment as PPD+ or PPD–. Corresponding unstimulated background controls were individually subtracted to compare dose and
time between naïve and immunized participants. N = 5 newborns, 4 PPD– adults and 5 PPD+ adults. Black stars compared BCG vs. theoretical mean 0.0; green
stars compared same condition between participants; blue stars compared the effect of BCG dose on a given participant/time or BCG time-point for the same
participant/dose. P = * < 0.05; ** < 0.01.
even wider variety of cytokines, including IL-1β, IL-2, IL-5,
IL-6, IL-7, CXCL8, IL-10, IL-12p70, IL-13, IL-15, IL-17, TNF-
α, TNF-β, IFN-α2, IFN-γ, GM-CSF, and CCL11. All of these
corresponded with cytokines induced by recall challenge of
infant leukocytes after neonatal BCG immunization in vivo,
including IL-1β, IL-2, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17,
TNF-α, and IFN-γ (20, 34, 35, 39–55) (Supplementary Table 4).
In contrast to BCG, HBV and PCV co-cultures produced a
markedly smaller array of cytokines and chemokines at relatively
lower concentrations. Adult HBV co-cultures showed significant
levels of CCL2, while newborn HBV co-cultures produced
significant IL-7, CXCL8, IFN-α2, and CCL11 (CCL2 was high
but without statistical power). Despite being measured, IL-5, IL-
13, or IFN-γ cytokines were not significant in vitro, an aspect
that is in agreement with HBsAg-recall challenge responses
from infants receiving only one birth dose of HBV in vivo
(Supplementary Table 4) (56). Adult PCV co-cultures generated
significant levels of IL-1α, IL-6, CXCL8, IFN-γ, GM-CSF, CCL2,
and CCL11; while newborn PCV co-cultures demonstrated
production of IL-1β, IL-6, IL-7, CXCL8, IL-10, IL-12p70, IFN-
α2, IFN-γ, and CCL11 (IL-13 and CCL2 were high but without
statistical power). In vivo, recall challenge of blood with PCV-
carrier protein Diphtheria CRM197 induced IL-1β, IL-5, IL-
6, IL-9, IL-10, IL-12, IL-13, TNF-α, and IFN-γ from infants
finishing a three dose PCV series (birth, 1, and 2 months of age)
(Supplementary Table 4) (37).
Subsequently, we tested the capacity of TCs to sense donor’s
immunological memory to vaccines by using negatively selected
autologous total CD4+ T cells from adults with recent Delayed-
Type Hypersensitivity (DTH) test against the mycobacterial
Purified Protein Derivative (PPD or Tuberculin), as well as
documented HBV vaccination status and active immunity to
HBV according to their Hepatitis B surface Antigen (HBsAg)
antibody (Ab) levels (>12.0 mIU/mL). CD4+ lymphocytes
were co-cultured for 7 days with autologous DCs from TCs
immunized in vitro with BCG, HBV, PCV, and the T-cell
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FIGURE 4 | Human tissue constructs model autologous age- and antigen 85A-specific responses after BCG immunization in vitro. (A) Assay design to assess
autologous Ag85A-specific recall-responses after BCG newborn in vitro immunization. DCs from age-specific TCs stimulated with BCG (1:10v/v) were co-cultured
with autologous naïve CD4+ T cells for 15 days (D15) and split (5,000 cells/well) to undergo antigen challenge for 10 more days (D25) using autologous monocytes
with either a peptide pool of antigen-specific Ag85A or a scrambled sequences control. (B) Autologous newborn Ag85A-specific recall-proliferation induced by BCG
in vitro immunization. Ag85A-specific lymphoproliferation (CPM) at days 20, 22, and 25 after peptide-challenge following assay design (A), as described in methods.
Corresponding non-specific background from scrambled sequence peptides were individually subtracted to Ag85A peptides CPMs (N = 6–7 participants/age group).
Black stars compared Ag85A-specific vs. theoretical mean 0.0. (C) Autologous newborn Ag85A-specific recall-cytokines induced by BCG in vitro immunization.
Cytokine profile induced by Ag85A-peptides challenge following assay design (A), as described in methods. DCs from age-specific TCs were either stimulated with
BCG (1:10v/v, red line) or left unstimulated (blue line) before co-cultured with autologous naïve CD4+ T cells for 15 days (D15) and split (5,000 cells/well) to undergo
antigen challenge for 10 more days (N = 6–7 participants per age group). Orange boxes highlight in vitro cytokines matching those induced in vivo by recall antigens
in infants vaccinated at birth with BCG (20, 34, 35, 39–55) (Supplementary Table 4). Black stars compared BCG vs. no BCG; green stars compared conditions
between age groups. P = * < 0.05; ** < 0.01; *** < 0.001.
independent (57) polysaccharide vaccine, Pneumococcal Vaccine
Polyvalent (PVP, Pneumovax©R 23), included for comparison
to the T-dependent PCV vaccine response (58). After 7 days
of culture (Figure 3B), adult and newborn CD4+ T cells
proliferated significantly in response to at least one of the
two concentrations tested (1:100v/v and 1:10v/v dilutions) for
every vaccine except PVP. Mirroring the requirement for at
least three infant doses of HBV (at birth, 2, and 6 months of
age) in vivo to try to achieve seroprotection (2), neonatal TC
HBV responses were detectable vs. unstimulated controls, but
were relatively lower than those from HBV-immunized adults.
The strong neonatal lymphoproliferative response to BCG,
coupled with a lack of a neonatal lymphoproliferation to PVP,
mirrored observations by clinical studies, further supporting
the hypothesis that the TC reflects immune responses relevant
in vivo (23, 59). To our knowledge, no studies have assessed
neonatal T cell responses after a single dose of PCV vaccine in
vivo, precluding direct comparison with the NTC readout for
this vaccine. However, the significant PCV response from ATCs
was in agreement with the expected age-dependent immune-
competency of adults against Streptococcus pneumoniae (2). BCG
results were further validated by measuring lymphoproliferation
through time and dose on adult donors grouped as PPD+ and
PPD- (Figure 3C). CD4+ lymphocytes stimulated by autologous
DCs from TCs immunized in vitro with BCG, proliferated in
a kinetic- and dose-dependent (1:100v/v vs. 1:10v/v) manner
above unstimulated controls, with extent of proliferation
mirroring the relative immunological memory of the participants
tested.
Autologous Antigen-Specific Recall
Responses by Age-Specific DCs From
BCG-Immunized Tissue Constructs
Next we assessed whether TC-derived DCs could stimulate single
antigen-specific responses in autologous naïve newborn CD4+
T cells after in vitro immunization with BCG vaccine. TCs
were left unstimulated or immunized with BCG (1:10v/v) in
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autologous plasma; autonomously generated DCs were then co-
cultured with autologous untouched naïve CD4+/CD45RA+ T
lymphocytes at a fixed ratio in the presence of autologous plasma
for up to 15 days, without media changes. At Day 15, rested T
cells were split (to 5,000 cells/well) and challenged for 10 days
more with autologous CD33+ monocytes and either scramble
control peptides or peptides spanning the entire protein sequence
of BCG antigen Ag85A (Figure 4A) (60). At D25, Ag85A-
challenge induced significant proliferation of newborn and
adult cultures above that of scramble-challenge, unchallenged
T cells or Ag85A-challenged autologous naïve T cells that
never received BCG-stimulated DCs (Figure 4B). Consistent
with their observed Ag85A-specific proliferation, newborn D25
supernatants demonstrated significant levels of IL-1α, IL-1β, IL-
2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, TNF-
α, TNF-β, IFN-γ, MIP-1α, and MIP-1β (Figure 4C); and adult
D25 supernatants produced IL-4, CXCL8, IL-12p40, IL-12p70,
TNF-α, TNF-β, IFN-γ, MIP-1α, and MIP-1β, as compared to
the non-vaccinated controls. Newborn cultures produced greater
concentrations of IL-4, IL-12p40, IL-12p70, and TNF-α, than
adults, while adult co-cultures produced greater concentrations
of IL-17. Eleven out of the 17 effector cytokines found on
newborn DC:T cell co-cultures vaccinated in vitro with BCG
(Supplementary Table 3) were also found after Ag85A-specific
challenge, including IL-1β, IL-2, IL-5, IL-6, IL-10, IL-12p70,
IL-13, IL-17, TNF-α, TNF-β, and IFN-γ. Of note, of these 11
cytokines, all but TNF-β (not studied in vivo) were produced
by leukocytes after antigen recall challenge in >4.5 month
old infants immunized with BCG at birth (20, 34, 35, 39–55)
(Supplementary Table 4).
Unlike newborn TNF responses to multiple other stimuli (e.g.,
Pam3) (24), TNF induction by Ag85A challenge was not inhibited
by the relatively high adenosine (Ado) concentration of neonatal
plasma. A possible explanation for this observation is that
Mycobacteria spp. can induce enhanced expression of ADA, a
biomarker enzyme that is elevated in TB infection (61), is critical
for development and function of T cells, as evidenced by ADA-
deficient SCID (35), and catabolizes Ado to the immunologically
inert Inosine. To assess this mechanistic hypothesis and
determine whether the NTC could model this relevant immune
mechanism in vitro, we characterized ADA activity in the
NTC. There are two forms of ADA, ADA-1, and ADA-2,
the latter with little activity over physiological concentrations
of Ado. Consistent with prior studies (62), newborn plasma
demonstrated significantly lower ADA-1 activity than adult
(Supplementary Figure 5). To enable ADA comparison of our
in vitro NTC results with the effect of BCG on newborns in vivo,
we measured ADA activity in blood plasma of 4 and 10 week-
old infants from a randomized clinical trial among low-birth-
weight infants in Guinea-Bissau (West Africa) (20) comparing
BCG at birth immunization vs. a delayed BCG vaccination
schedule (Figure 5A). ADA-2 increased with age in both groups,
whereas ADA-1 increased from 4 to 10 weeks among BCG-
vaccinated but not among controls. ADA-1 activity at 10 weeks
old increased significantly in association to a birth dose of
BCG. Since birth weight was strongly correlated with receipt
of pentavalent or the subsequent BCG in the control group,
a sensitivity analysis using linear regression was additionally
performed. Controlling for birth weight did not change ADA
results. In agreement with these results, and with the increased
ADA activity induced by BCG on human adult MCs in vitro (63),
a single dose of BCG induced a significant increase in ADA-1
activity in both the NTC and the ATC after 48 h in vitro, with
a greater relative effect in newborns, such that BCG increased the
relatively basal neonatal ADA-1 activity to a level similar to adults
(Figure 5B).
Autologous Antigen-Specific Recall
Responses by Age-Specific DCs From
HBV-Immunized Tissue Constructs
As HBV is a standard single-antigen alum-adjuvanted licensed
vaccine containing a viral like particle of hepatitis B surface
antigen (HBsAg) given at birth across the globe (64), we next
modeled immunity to this vaccine in vitro. Considering that DCs
from HBV-immunized TCs induced a modest but significant
proliferation of newborn CD4T cells at 1:100v/v dilution
(Figure 3B) and that, a peptide pool approach successfully
demonstrated BCG recall Ag-specific proliferative responses
(Figure 4B), we followed a similar approach for antigen-
challenge after HBV. Anticipating a positive memory response,
we recruited HBV vaccinated adult donors. DCs from HBV-
stimulated TCs were co-cultured with autologous total CD4+
T cells up to D15 before splitting cells and challenging them
for an additional 10 days with autologous monocytes and either
peptides spanning the entire protein sequence of HBV antigen
HBsAg (22) or background control sequence-scrambled peptides
(Supplementary Table 1 and Supplementary Figure 6). As
noted in vivo after a single dose of HBV, with a substantial
proportion of HBV non-responders and often negligible
lymphoproliferation after infant HBsAg recall challenge
(2, 56, 64–66), a single dose of vaccine resulted in insufficient
detection of newborn HBsAg-associated recall proliferation
above scrambled control. As effective HBV immunization
in vivo typically requires >1 dose, we next implemented a
TC boosting strategy in vitro. To provide this boosting HBV
dose to already primed DC:T cell co-cultures, a second set
of autologous TCs were in vitro-immunized with same HBV
vaccine lot and dose (1:100v/v) and resulting autologous DCs
were added to ongoing co-cultures at D7 (boost). Of note,
second dose after a birth-dose of HBV is only recommended
after passing 4-weeks of life (neonatal phase) (2, 64); by then,
infant plasma is known to be distinct from that of newborns
and adults (2, 28, 62). While in vitro HBV boosting would
require using autologous infant (not neonatal) plasma from
that point onward, from an in vitro modeling perspective there
are challenging limitations in drawing the large volumes of
autologous infant blood (>1 month of age) required for this
step. Thus, to approximate infant plasma in vitro, we changed
the natural relative presence of soluble immune-modulators
halfway between neonatal and adult levels by mixing 1:1v/v
the plasma of the newborn and the adult routinely tested
side-by-side on each one of these assays. Accordingly, besides
testing vaccine boosting in vitro with 100% neonatal plasma,
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FIGURE 5 | BCG vaccine induces plasma ADA activity in vivo and in vitro. (A) ADA-1 and ADA-2 activities in blood samples from a clinical study in Guinea-Bissau
comparing birth-BCG (BCG) vs. delayed-BCG (Ø). Blood samples were obtained at ∼4 and ∼10 weeks of age (before immunization of delayed-BCG group). Each dot
represents a study participant tested. The 4 weeks old infants group included 183 plasmas from early BCG and 131 from delayed-BCG group (Ø). The 10 weeks old
infants group consisted of 169 plasmas from early BCG and 42 from delayed-BCG group (Ø). (B) ADA-1 activity in plasma from TCs immunized in vitro with BCG.
Age-specific TCs were either stimulated with BCG (1:10v/v) or left unstimulated (Ø) and 48 h later plasmas were collected for ADA-1 activity testing (N = 10–13
participants per age group). U/L = Units per liter. P= * < 0.05; ** < 0.01; *** < 0.001.
we included a mixed plasma condition from the boost point
onward (Figure 6A). Indeed, whereas no HBsAg-associated
proliferation was detected above scrambled control (D31)
when boosting under autologous newborn plasma, significant
increase in HBsAg-specific proliferation was achieved when
boosting under mixed plasma (Figure 6B). Measurement of
antibodies against HBsAg (anti-HBsAg-Abs) in plasmas used for
these HBV assays (Supplementary Table 2) demonstrated
that mean anti-HBsAg-Ab titers were not significantly
different between test conditions (Supplementary Figure 7),
suggesting they did not account for the observed effect by mixed
plasma.
To confirm our impression of the generation of HBsAg-
specific responses in vitro, we characterized the HBsAg-specific
T cell clones associated with HBV boosting under different
plasma types. To this end, cells from three experiments
(total N = 3 per age group) were taken at seven points
throughout cultures (Figure 6A) and sent de-identified to
a third-party laboratory for high-throughput sequencing of
the CDR3 region using the ImmunoSEQ©R assay (Adaptive
Biotechnologies©R ; Seattle, WA). A pair-wise Morisita overlap
index analysis for both, the nucleotide (NT) and predicted
aminoacid (AA) sequences of detected TCRs of all samples
(Supplementary Figure 8), indicated an acceptable level
of independency (TCR clustering) between the six non-
consanguineous participants with no overlap with the HUVEC
control. Analysis of the number and frequency of detected
productive rearranged TCR sequences, those likely reflecting
single functional T cell, was focused on TCRs linked to HBV
in vitro immunization (Figure 6C), as described in Methods.
In contrast to the use of autologous plasma, analysis of the
TCR repertoire resulting from NTCs boosted with HBV under
1:1v/v mixed plasma demonstrated a significant increase in
number and frequency of HBsAg-associated TCR clones,
as compared to scrambled control peptides. For ATCs the
opposite pattern was observed, with mixed plasma during
boosting significantly inhibiting expansion of HBsAg-specific
clones.
DISCUSSION
Age-specific modeling of human vaccine responses in vitro
may be crucial to accelerate and de-risk vaccine development
as costly animal models reflect species-specific immunity and
it is not feasible to conduct large scale human clinical
trials in every target population for each potential candidate
vaccine formulation including diverse combinations of vaccinal
antigen, adjuvantation and formulation systems. In particular,
modeling of vaccine-induced autologous naïve CD4+ T cell
responses is important since T cell help to germinal center
B cells is essential for durable vaccine-induced humoral
immunity (67) and >90% of licensed U.S. vaccines are
based on antigenic proteins, likely to initiate T cell responses
in vivo (68). In this context, we report the first human
in vitro system comprised of entirely human components
that faithfully models age- and antigen-specific responses to
licensed vaccines. Here, autonomously generated DCs from
our age-specific microphysiologic human Tissue Constructs
immunized in vitro with licensed pediatric vaccines, induced
autologous naïve CD4+ T cell responses and single antigen-
specific recall challenge responses, similar to those observed in
vivo.
Our human TC model differs substantially from prior
seemingly similar immunological in vitro approaches (10, 16–
19) in its emphasis on: (1) immune ontogeny, including
newborns who are at highest risk of infection and receive
the greatest number of vaccines (69); (2) composition from
exclusively endotoxin-free human biomaterials, providing
a low background to enable detection of vaccine-induced
antigen-specific responses; and (3) microphysiology, preserving
autologous complex humoral and cellular signals that direct
autonomous migration and differentiation of monocytes into
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FIGURE 6 | Human tissue constructs model autologous age- and antigen-specific responses after HBV immunization in vitro. (A) Assay design to assess autologous
HBsAg-specific recall-responses after HBV newborn in vitro immunization. DCs from age-specific TCs stimulated with HBV (1:100v/v) were co-cultured (PRIME) with
autologous CD4+ T cells©1 for 7 days and then re-stimulated (BOOST) with a second round of autologous DCs form HBV-stimulated TCs (D7). At D21 of further
culture (©2 and©5 ), resting T cells were collected, counted and split (5,000 cells/well) to undergo antigen challenge (Ag-CHALLENGE) for another 10 days (D31,
©3 ,©4 ,©6 , and©7 ) using autologous monocytes and a peptide pool approach (HBsAg vs. scrambled sequence control). From D7 onward, half the experiments
continue their culture under either 100% autologous plasma (green) or a 1:1v/v mix of newborn and adult plasmas (red). (B) Autologous newborn HBsAg-specific
recall-proliferation induced by HBV in vitro immunization. Ag-challenge proliferation (CPM) was assessed at D31 for conditions©4 and (100% autologous plasma in
green)©6 and©7 and (1:1v/v mixed plasma in red) on each age group according to assay design (A), as described in methods. N = 10–15 participants/age group
with ≥7 technical replicas/condition. (C) HBV-associated challenge-specific TCRs (D31). Cell samples from steps©1 ,©2 ,©3 ,©4 ,©5 ,©6 , and©7 according to
assay design (A) were taken for DNA extraction and high-throughput sequencing of the TCRβ CDR3 region, as described in Methods (N = 3/age-group). The sum of
frequencies of productively rearranged non-shared TCRs from each peptide-challenge sample at D31 (©3 ,©4 ,©6 , and©7 ) that were also detected at corresponding
D21 samples (©2 or©5 ), were plotted. The number of HBV-associated challenge-specific TCRs found (yellow areas of Venn diagrams) is indicated inside
corresponding column. Blue numbers in Venn diagrams refer to newborns and black to adults. Green color refers to conditions using only 100% autologous plasma.
Red color refers to conditions using mixed plasma from boost step onward. P = * < 0.05; ** < 0.01; *** < 0.001.
DCs and their escape from tissues as age-specific antigen-
presenting cells carrying vaccinal antigens, mirroring the
efficient constitutive differentiation of monocytes into
migratory DCs that occurs in vivo (11). Key to our culture
approach is the use of relatively inexpensive autologous
heparinized non-heated plasma that preserves age-specific
factors that naturally shape innate and adaptive immune
responses in vivo (31). Autonomous differentiation of primary
monocytes into DCs occurred in autologous plasma with
no exogenous cytokines or xenogenic additives, avoiding
cellular differentiation to phenotypes that may not be relevant
in vivo (70).
Providing a more natural microenvironment with minimal
manipulation likely contributed to the ability of our human
in vitro system to mirror in vivo vaccine responses, including:
(1) innate DC maturation and migration in response to
adjuvants and the self-adjuvanted BCG vaccine (71); (2)
BCG-induced increase of plasma ADA activity in infants,
a reported in vivo biomarker of infant BCG immunization
(72) that we independently confirmed; (3) limited T
lymphocyte proliferation in response to the T cell-independent
pneumococcal polysaccharide vaccine (73); (4) vaccine-induced
patterns of antigen-recall T cell cytokines, chemokines,
and lymphoproliferation (2, 20, 34, 35, 37, 39–56, 64–66)
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(Supplementary Table 4); and (5) single-antigen responses with
dosing and plasma requirements matching those needed to
generate protective immunity in vivo [i.e., a single dose for BCG
(23, 59) vs. multiple doses for HBV (64)]. Moreover, comparison
of newborn and adult responses demonstrated that multiple
aspects of our results also match age-specific differences noted
in other human in vitro and in vivo studies (2, 24, 31, 32, 74),
suggesting the validity of our approach: (i) greater and broader
adult DC maturation and lymphoproliferation to a range of
adjuvants and vaccines (69), with the notable exception of
robust neonatal DC maturation by TLR7/8A, recently shown
to be a highly effective neonatal vaccine adjuvant in vivo (71);
(ii) increased responsiveness of newborn leukocytes in the
presence of adult plasma, and lower responsiveness of adult cells
cultured in newborn plasma (24); (iii) lower newborn plasma
ADA activity baseline (62); (iv) higher adult cognate T cell
responsiveness paralleling study participant vaccination history
and immune status (74); and a narrower and Th1-polarized
cytokine profile by BCG-immunized adults (75) as compared
to a broader Th1/Th2 mixed profile by newborns in vivo
(20, 34, 35, 39–55).
Few published studies have examined antigen presentation by
human neonates in vitro (76–82), with only two demonstrating
autologous naïve T cell responses toward a single-antigen (81,
82); neither of which used licensed newborn vaccines and both of
which employed cytokines to differentiate monocytes into DCs,
as well as exogenous additives to enforce T cell responses in vitro,
approaches that may intrinsically compromise the physiologic
relevance of the findings and their in vivo translation. Moreover,
to our knowledge our in vitro platform is the first culture system
that achieved the induction of human newborn autologous
naïve antigen-specific CD4+ T lymphocyte responses to licensed
vaccines in vitromatching responses observed in vivo.
Overall, our results strongly suggest that microphysiologic in
vitro cultures can model both innate and adaptive autologous
age-specific human immune responses to adjuvants and licensed
vaccines. Our culture approach demonstrates advantages over
clinical trials as it compares the same study participant for both
control and test conditions, thereby enhancing statistical power
by limiting unwanted genetic and epigenetic variability intrinsic
to human clinical trials, and enables large-scale human studies
of combinations of candidate vaccinal antigens, adjuvantation
systems and formulations, which is not feasible in vivo given the
costs of conducting large-scale human clinical trials. As with any
new technology, our culture model also has limitations such as
the lack of physiologic fluid flow, natural self-driven DC:T cell
interactions (as fixed DC:T cell ratios were used for proof of
concept comparisons) and naïve B cell Ab responses, a common
vaccine correlate of protection (68). Future studies should
explore use of whole blood and interstitial flow (microfluidics)
enabling natural transit of migratory cells to reflect the
complexity of cell migration and cell-cell interactions inherent
to tissues in vivo. Modeling lymphoid cell heterogeneity will
likely be necessary to generate autologous functional germinal
centers and Ab production; a technical aspect that thus far
has apparently only been demonstrated under markedly non-
physiologic conditions (83).
In sum, our microphysiologic culture system enables
autonomous generation of human DCs that can stimulate
autologous naïve CD4T cells to replicate age-specific single-
antigen immune responses to licensed vaccines, as noted in
vivo. Our newborn and adult culture systems offer practical and
technical advantages over current systems and in principle can
be used to model responses to additional vulnerable populations
such as the frail, elderly and chronically ill. Our approach
offers a unique platform for human pre-clinical immunological
studies informing age-targeted vaccine effectiveness in vitro to
accelerate, enhance, and de-risk vaccine development, including
design of single-dose early life vaccines, that can increase global
vaccine coverage, reduce infant vulnerability, and provide major
public health benefits (2).
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this manuscript will
be made available by the authors, without undue reservation, to
any qualified researcher. Some data will be deposited to NIAID’s
ImmPort website.
AUTHOR CONTRIBUTIONS
GS-S conceived, designed and executed the experiments,
analyzed the data, and wrote the manuscript. PF, CS, IB, and GM
assisted with execution of experiments and provided manuscript
edits. KS-A analyzed TCR data. DH assisted with TCR data
analysis and provided manuscript edits. KJ and CB designed and
recruited the study cohort in Guinea-Bissau (20) whose plasma
samples were studied and assisted with ADA data analyses.
OL provided key intellectual input, funding, and infrastructure
support to this project, and edited the manuscript.
FUNDING
This study was supported by grants to OL from the Bill &
Melinda Gates Foundation (OPPGH5284) and the National
Institutes of Health/National Institute of Allergy and Infectious
Diseases (NIH/NIAID), including those on Infant Immunity
(1RO1AI100135-01), Molecular Mechanisms of Combination
Adjuvants (U01AI124284) and the Human Immunology
Project Consortium (U19AI118608-01A1). This work was also
supported by an internal Boston Children’s Hospital Department
of Medicine award to the Precision Vaccines Program, two
consecutive internal Boston Children’s Hospital Technology
Development Fund awards to GS-S and OL, and a grant from
the Danish National Research Foundation to KJ and CB of The
Research Center for Vitamins and Vaccines (DNRF108).
ACKNOWLEDGMENTS
We acknowledge Drs. Michael Wessels, Richard Malley, Simon
Van Haren, Annette Scheid, David Dowling and Clare Baecher-
Allan for helpful conversations; Dr. Thomas Winters and NPC
Christine Cadegan for recruitment of adult study participants;
Frontiers in Immunology | www.frontiersin.org 16 November 2018 | Volume 9 | Article 2634
Sanchez-Schmitz et al. Tissue Constructs Model Age-Specific Immunity
Drs. Matthew Pettengill and Sweta Joshi for ADA and endotoxin
testing; Allan G. Schmitz-Martinez for helpful revisions; Maria
Crenshaw, for administrative support, as well as the delivery staff
of Brigham and Women’s Hospital and Beth Israel Deaconess
Medical Center for their assistance with cord blood collections.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2018.02634/full#supplementary-material
REFERENCES
1. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function
by Toll-like receptors: distinct responses in newborns and the elderly.
Immunity (2012) 37:771–83. doi: 10.1016/j.immuni.2012.10.014
2. Sanchez-Schmitz G, Levy O. Development of newborn and infant vaccines.
Sci Transl Med. (2011) 3:90ps27. doi: 10.1126/scitranslmed.3001880
3. Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk
in vaccine research and development quantified. PLoS ONE (2013) 8:e57755.
doi: 10.1371/journal.pone.0057755
4. Leist M, Hartung T. Inflammatory findings on species extrapolations:
humans are definitely no 70-kg mice. Arch Toxicol. (2013) 87:563–7.
doi: 10.1007/s00204-013-1038-0
5. Vaccari M, Franchini G. T cell subsets in the germinal center:
lessons from the macaque model. Front Immunol. (2018) 9:348.
doi: 10.3389/fimmu.2018.00348
6. Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-
presenting cells: can anything replace a dendritic cell? Nat Rev Immunol.
(2014) 14:719–30. doi: 10.1038/nri3754
7. Benvenuti F. The dendritic cell synapse: a life dedicated to T cell activation.
Front Immunol. (2016) 7:70. doi: 10.3389/fimmu.2016.00070
8. Tapia-Calle G, Stoel M, de Vries-Idema J, Huckriede A. Distinctive
responses in an in vitro human dendritic cell-based system upon stimulation
with different influenza vaccine formulations. Vaccines (2017) 5:E21.
doi: 10.3390/vaccines5030021
9. Randolph GJ, Ochando J, Partida-Sanchez S. Migration of dendritic cell
subsets and their precursors. Annu Rev Immunol. (2008) 26:293–316.
doi: 10.1146/annurev.immunol.26.021607.090254
10. Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller
WA. Differentiation of monocytes into dendritic cells in a
model of transendothelial trafficking. Science (1998) 282:480–3.
doi: 10.1126/science.282.5388.480
11. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA.
Differentiation of phagocytic monocytes into lymph node dendritic cells
in vivo. Immunity (1999) 11:753–61. doi: 10.1016/S1074-7613(00)80149-1
12. Randolph GJ, Sanchez-Schmitz G, Angeli V, Randolph GJ, Sanchez-Schmitz
G, Angeli V. Factors and signals that govern the migration of dendritic
cells via lymphatics: recent advances. Springer Semin Immunopathol. (2005)
26:273–87. doi: 10.1007/s00281-004-0168-0
13. Randolph GJ, Beaulieu S, Pope M, Sugawara I, Hoffman L, Steinman RM,
et al. A physiologic function for p-glycoprotein (MDR-1) during themigration
of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci
USA. (1998) 95:6924–9. doi: 10.1073/pnas.95.12.6924
14. Flores-Romo L. In vivo maturation and migration of dendritic
cells. Immunology (2001) 102:255–62. doi: 10.1046/j.1365-2567.2001.
01204.x
15. Townsley MI. Structure and composition of pulmonary arteries,
capillaries, and veins. Compr Physiol. (2012) 2:675–709. doi: 10.1002/cphy.
c100081
16. Randolph GJ, Sanchez-Schmitz G, Liebman RM, Schäkel K. The CD16+
(FcγRIII+) subset of human monocytes preferentially becomes migratory
dendritic cells in a model tissue setting. J Exp Med. (2002) 196:517–27.
17. Qu C, Moran TM, Randolph GJ. Autocrine type I IFN and
contact with endothelium promote the presentation of influenza
A virus by monocyte-derived. APJ Immunol C (2003) 170:1010–8.
doi: 10.4049/jimmunol.170.2.1010
18. Schanen BC, Drake DR III. A novel approach for the generation of human
dendritic cells from blood monocytes in the absence of exogenous factors.
J Immunol Methods (2008) 335:53–64. doi: 10.1016/j.jim.2008.02.021
19. Higbee RG, Byers AM, Dhir V, Drake D, Fahlenkamp HG, Gangur J, et al.
An immunologic model for rapid vaccine assessment – a clinical trial in a
test tube. Altern Lab Anim. (2009) 37 (Suppl. 1):19–27.
20. Jensen KJ, Larsen N, Biering-Sørensen S, Andersen A, Eriksen HB, Monteiro
I, et al. Heterologous immunological effects of early BCG vaccination in low-
birth-weight infants in Guinea-Bissau: a randomized-controlled trial. J Infect
Dis. (2015) 211:956–67. doi: 10.1093/infdis/jiu508
21. Huygen K, Lozes E, Gilles B, Drowart A, Palfliet K, Jurion F, et al. Mapping
of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A
in mice infected with live Mycobacterium bovis. BC Infect Immun. (1994)
62:363–70.
22. Desombere I, Gijbels Y, Verwulgen A, Leroux-Roels G. Characterization of
the T cell recognition of hepatitis B surface antigen (HBsAg) by good and
poor responders to hepatitis B vaccines. Clin Exp Immunol. (2000) 122:390–9.
doi: 10.1046/j.1365-2249.2000.01383.x
23. Merck & Co. I. PNEUMOVAX©R 23 (pneumococcal vaccine polyvalent).
Prescribing information. (2016).
24. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels
MR. The adenosine system selectively inhibits TLR-mediated TNF-alpha
production in the human newborn. J Immunol. (2006) 177:1956–66.
doi: 10.4049/jimmunol.177.3.1956
25. vanMontfoort N, van der Aa E, van den Bosch A, Brouwers H, Vanwolleghem
T, Janssen HLA, et al. Hepatitis B virus surface antigen activates myeloid
dendritic cells via a soluble CD14-dependent mechanism. J Virol. (2016)
90:6187–99. doi: 10.1128/JVI.02903-15
26. Ben Haij N, Planès R, Leghmari K, Serrero M, Delobel P, Izopet J, et al. HIV-
1 tat protein induces production of proinflammatory cytokines by human
dendritic cells and monocytes/macrophages through engagement of TLR4-
MD2-CD14 complex and activation of NF-kappaB pathway. PLoSONE (2015)
10:e0129425. doi: 10.1371/journal.pone.0129425
27. Sánchez-Torres C, García-Romo GS, Cornejo-Cortés MA, Rivas-Carvalho
A, Sánchez-Schmitz G.Sanchez-Torres C, et al. CD16+ and CD16− human
blood monocyte subsets differentiate in vitro to dendritic cells with different
abilities to stimulate CD4+ T cells. Int Immunol. (2001) 13:1571–81.
doi: 10.1093/intimm/13.12.1571
28. PrabhuDas M, Adkins B, Gans H, King C, Levy O, Ramilo O, et al. Challenges
in infant immunity: implications for responses to infection and vaccines. Nat
Immunol. (2011) 12:189–94. doi: 10.1038/ni0311-189
29. Kumari M, Saxena RK. Relative efficacy of uptake and presentation
of Mycobacterium bovis BCG antigens by type I mouse lung epithelial
cells and peritoneal macrophages. Infect Immun. (2011) 79:3159–67.
doi: 10.1128/IAI.05406-11
30. Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung MW, Parsons
JM, et al. Using synthetic templates to design an unbiased multiplex PCR
assay. Nat Commun. (2013) 4:2680. doi: 10.1038/ncomms3680
31. Pettengill MA, van Haren SD, Levy O. Soluble mediators regulating immunity
in early life. Front Immunol. (2014) 5:457. doi: 10.3389/fimmu.2014.00457
32. Levy O, Suter EE, Miller RL,Wessels MR. Unique efficacy of Toll-like receptor
8 agonists in activating human neonatal antigen-presenting cells. Blood (2006)
108:1284–90. doi: 10.1182/blood-2005-12-4821
33. Potolicchio I, Chitta S, Xu X, Fonseca D, Crisi G, Horejsi V, et al.
Conformational variation of surface class II MHC proteins during myeloid
dendritic cell differentiation accompanies structural changes in lysosomal
MII. J Immunol C (2005) 175:4935–47. doi: 10.4049/jimmunol.175.8.4935
34. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria:
the human model. Annu Rev Immunol. (2002) 20:581–620.
doi: 10.1146/annurev.immunol.20.081501.125851
35. Pachlopnik Schmid J, Güngör T, Seger R. Modern management of primary
T-cell immunodeficiencies. Pediatr Allergy Immunol. (2014) 25:300–13.
Frontiers in Immunology | www.frontiersin.org 17 November 2018 | Volume 9 | Article 2634
Sanchez-Schmitz et al. Tissue Constructs Model Age-Specific Immunity
36. Teschner D, Distler E, Wehler D, Frey M, Marandiuc D, Langeveld K, et al.
Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new
approach for GVHDprophylaxis. BoneMarrow Transplant. (2014) 49:138–44.
doi: 10.1038/bmt.2013.114
37. van den Biggelaar AH, Pomat W, Bosco A, Phuanukoonnon S, Devitt CJ,
Nadal-Sims MA, et al. Pneumococcal conjugate vaccination at birth in a
high-risk setting: no evidence for neonatal T-cell tolerance. Vaccine (2011)
29:5414–20. doi: 10.1016/j.vaccine.2011.05.065
38. Thurley K, Gerecht D, Friedmann E, Höfer T. Three-dimensional gradients
of cytokine signaling between T Cells. PLoS Comput Biol. (2015) 11:e1004206.
doi: 10.1371/journal.pcbi.1004206
39. Murray RA, Mansoor N, Harbacheuski R, Soler J, Davids V, Soares A,
et al. Bacillus calmette guerin vaccination of human newborns induces a
specific, functional CD8+ T cell response. J Immunol. (2006) 177:5647–51.
doi: 10.4049/jimmunol.177.8.5647
40. Randhawa AK, Shey MS, Keyser A, Peixoto B, Wells RD, de Kock M, et al.
Association of human TLR1 and TLR6 deficiency with altered immune
responses to BCG vaccination in South African infants. PLoS Pathog. (2011)
7:e1002174. doi: 10.1371/journal.ppat.1002174
41. Djuardi Y, Sartono E, Wibowo H, Supali T, Yazdanbakhsh M. A
longitudinal study of BCG vaccination in early childhood: the development
of innate and adaptive immune responses. PLoS ONE (2010) 5:e14066.
doi: 10.1371/journal.pone.0014066
42. Sartono E, Lisse IM, Terveer EM, van de Sande PJ, Whittle H, Fisker
AB, et al. Oral polio vaccine influences the immune response to
BCG vaccination. A natural experiment. PLoS ONE (2010) 5:e10328.
doi: 10.1371/journal.pone.0010328
43. Burl S, Adetifa UJ, Cox M, Touray E, Ota MO, Marchant A, et al. Delaying
bacillus calmette-guerin vaccination from birth to 4 1/2 months of age
reduces postvaccination Th1 and IL-17 responses but leads to comparable
mycobacterial responses at 9 months of age. J Immunol. (2010) 185:2620–8.
doi: 10.4049/jimmunol.1000552
44. Akkoc T, Aydogan M, Yildiz A, Karakoc-Aydiner E, Eifan A, Keles
S, et al. Neonatal BCG vaccination induces IL-10 production by
CD4+ CD25+ T cells. Pediatr Allergy Immunol. (2010) 21:1059–63.
doi: 10.1111/j.1399-3038.2010.01051.x
45. Kagina BM, Abel B, Bowmaker M, Scriba TJ, Gelderbloem S, Smit E,
et al. Delaying BCG vaccination from birth to 10 weeks of age may result
in an enhanced memory CD4T cell response. Vaccine (2009) 27:5488–95.
doi: 10.1016/j.vaccine.2009.06.103
46. Finan C, Ota MO, Marchant A, Newport MJ. Natural variation in immune
responses to neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG)
Vaccination in a Cohort of Gambian infants. PLoS ONE (2008) 3:e3485.
doi: 10.1371/journal.pone.0003485
47. Matee M, Lahey T, Vuola JM, Mtei L, Cole BF, Bakari M, et al.
Baseline mycobacterial immune responses in HIV-infected adults primed
with bacille Calmette-Guerin during childhood and entering a tuberculosis
booster vaccine trial. J Infect Dis. (2007) 195:118–23. doi: 10.1086/
509896
48. Watkins ML, Semple PL, Abel B, HanekomWA, Kaplan G, Ress SR. Exposure
of cord blood to Mycobacterium bovis BCG induces an innate response but
not a T-cell cytokine response. Clin Vaccine Immunol. (2008) 15:1666–73.
doi: 10.1128/CVI.00202-08
49. Vekemans J, Amedei A, Ota MO, D’Elios MM, Goetghebuer T, Ismaili J,
et al. Neonatal bacillus Calmette-Guerin vaccination induces adult-like IFN-
gamma production by CD4+ T lymphocytes. Eur J Immunol. (2001) 31:1531–
5. doi: 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
50. Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, Gelderbloem
SJ, et al. Bacillus Calmette-Guerin vaccination of human newborns induces
T cells with complex cytokine and phenotypic profiles. J Immunol. (2008)
180:3569–77. doi: 10.4049/jimmunol.180.5.3569
51. Marchant A, Goetghebuer T, Ota MO, Wolfe I, Ceesay SJ, De Groote D,
et al. Newborns develop a Th1-type immune response toMycobacterium bovis
bacillus Calmette-Guerin vaccination. J Immunol. (1999) 163:2249–55.
52. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF.
Relationship of the manifestations of tuberculosis to CD4 cell counts in
patients with human immunodeficiency virus infection. Am Rev Respir Dis.
(1993) 148:1292–7. doi: 10.1164/ajrccm/148.5.1292
53. Oni T, Gideon HP, Bangani N, Tsekela R, Seldon R, Wood K, et al.
Smoking BCG, and employment and the risk of tuberculosis infection
in HIV-infected persons in South Africa. PLoS ONE (2012) 7:e47072.
doi: 10.1371/journal.pone.0047072
54. Oni T, Gideon HP, Bangani N, Tsekela R, Seldon R,Wood K, et al. Risk factors
associated with indeterminate gamma interferon responses in the assessment
of latent tuberculosis infection in a high-incidence environment. Clin Vaccine
Immunol. (2012) 19:1243–7. doi: 10.1128/CVI.00166-12
55. Arikan C, Bahceciler NN, Deniz G, Akdis M, Akkoc T, Akdis CA,
et al. Bacillus Calmette-Guerin-induced interleukin-12 did not additionally
improve clinical and immunologic parameters in asthmatic children treated
with sublingual immunotherapy. Clin Exp Allergy (2004) 34:398–405.
doi: 10.1111/j.1365-2222.2004.01869.x
56. Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Whittle H, Lambert
PH, et al. Hepatitis B immunisation induces higher antibody and memory
Th2 responses in new-borns than in adults. Vaccine (2004) 22:511–9.
doi: 10.1016/j.vaccine.2003.07.020
57. Roth A, Glaesener S, Schütz K, Meyer-Bahlburg A. Reduced number of
transitional and naive B cells in addition to decreased BAFF levels in response
to the T cell independent immunogen pneumovax(R)23. PLoS ONE (2016)
11:e0152215.doi: 10.1371/journal.pone.0152215
58. Wyeth Pharmaceuticals I. Pneumococcal 13-valent Conjugate Vaccine. Package
insert. (2016).
59. Share JB. Description of BCG Vaccine SSI. Institut SS (2011).
60. Huygen K. The Immunodominant T-cell epitopes of the mycolyl-transferases
of the antigen 85 complex of M. tuberculosis. Front Immunol. (2014) 5:321.
doi: 10.3389/fimmu.2014.00321
61. Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N, et al. A
systematic review of rapid diagnostic tests for the detection of tuberculosis
infection. Health Technol Assess. (2007) 11:1–196. doi: 10.3310/hta11030
62. Pettengill M, Robson S, Tresenriter M, Millán JL, Usheva A, Bingham T, et al.
Soluble ecto-5’-nucleotidase (5’-NT), alkaline phosphatase, and adenosine
deaminase (ADA1) activities in neonatal blood favor elevated extracellular
adenosine. J Biol Chem. (2013) 288:27315–26. doi: 10.1074/jbc.M113.4
84212
63. Kashyap RS, Husain AA, Morey SH, Panchbhai MS, Deshpande PS, Purohit
HJ, et al. Assessment of immune response to repeat stimulation with BCG
vaccine using in vitro PBMC model. J Immune Based Ther Vaccines (2010)
8:3. doi: 10.1186/1476-8518-8-3
64. Merck & Co I. Package Insert for RECOMBIVAX HB. (2016).
65. Avanzini MA, Belloni C, Soncini R, Ciardelli L, de Silvestri A, Pistorio A,
et al. Increment of recombinant hepatitis B surface antigen-specific T-cell
precursors after revaccination of slow responder children. Vaccine (2001)
19:2819–24. doi: 10.1016/S0264-410X(01)00007-X
66. Nyström J, Cardell K, Björnsdottir TB, Fryden A, Hultgren C, Sällberg M.
Improved cell mediated immune responses after successful re-vaccination
of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine
using the combined hepatitis A and B vaccine. Vaccine (2008) 26:5967–72.
doi: 10.1016/j.vaccine.2008.08.054
67. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly -
TFH cells in human health and disease. Nat Rev Immunol. (2013) 13:412–26.
doi: 10.1038/nri3447
68. Administration, U.S.F.a.D. Vaccines Licensed for Use in the United States.
(2018). Available from: http://www.fda.gov/BiologicsBloodVaccines/
Vaccines/ApprovedProducts/ucm093833.htm (Accessed October 11, 2016).
69. Kollmann TR, Kampmann B,Mazmanian SK,Marchant A, Levy O. Protecting
the newborn and young infant from infectious diseases: lessons from immune
ontogeny. Immunity (2017) 46:350–63. doi: 10.1016/j.immuni.2017.03.009
70. Guo X, Zhou Y, Wu T, Zhu X, Lai W, Wu L. Generation of mouse
and human dendritic cells in vitro. J Immunol Methods (2016) 432:24–9.
doi: 10.1016/j.jim.2016.02.011
71. Dowling DJ, Scott EA, Scheid A, Bergelson I, Joshi S, Pietrasanta C,
et al. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating
effects of the live BCG vaccine and enhance neonatal innate and
adaptive immune responses. J Allergy Clin Immunol. (2017) 140:1339–50.
doi: 10.1016/j.jaci.2016.12.985
72. Thora S, Rajsekaran P, Chhaparwal BC. Serum adenosine deaminase
estimation in relation to BCG vaccination. Indian Pediatr. (1995) 32:1087–8.
Frontiers in Immunology | www.frontiersin.org 18 November 2018 | Volume 9 | Article 2634
Sanchez-Schmitz et al. Tissue Constructs Model Age-Specific Immunity
73. Karasartova D, Gazi U, Tosun O, Gureser AS, Sahiner IT, Dolapci M,
et al. Anti-pneumococcal vaccine-induced cellular immune responses in post-
traumatic splenectomized individuals. J Clin Immunol. (2017) 37:388–96.
doi: 10.1007/s10875-017-0397-3
74. Kowalewicz-Kulbat M, Szpakowski P, Locht C, Biet F, Kaplonek P, Krawczyk
KT, et al. Tuberculin skin test reaction is related to memory, but not naive
CD4(+) T cell responses to mycobacterial stimuli in BCG-vaccinated young
adults. Vaccine (2018) 36:4566–77. doi: 10.1016/j.vaccine.2018.05.068
75. Hoft DF, Kemp EB, Marinaro M, Cruz O, Kiyono H, McGhee JR,
et al. A double-blind, placebo-controlled study of Mycobacterium-
specific human immune responses induced by intradermal bacille
Calmette-Guerin vaccination. J Lab Clin Med. (1999) 134:244–52.
doi: 10.1016/S0022-2143(99)90204-4
76. Tonon S, Goriely S, Aksoy E, Pradier O, Del Giudice G, Trannoy
E, et al. Bordetella pertussis toxin induces the release of inflammatory
cytokines and dendritic cell activation in whole blood: impaired responses
in human newborns. Eur J Immunol. (2002) 32:3118–25. doi: 10.1002/1521-
4141(200211)32:11<3118::AID-IMMU3118>3.0.CO;2-B
77. Goriely S, Van Lint C, Dadkhah R, Libin M, De Wit D, Demonté
D, et al. A defect in nucleosome remodeling prevents IL-12(p35) gene
transcription in neonatal dendritic cells. J Exp Med. (2004) 199:1011–6.
doi: 10.1084/jem.20031272
78. Philbin VJ, Dowling DJ, Gallington LC, Cortés G, Tan Z, Suter EE, et al.
Imidazoquinoline Toll-like receptor 8 agonists activate human newborn
monocytes and dendritic cells through adenosine-refractory and caspase-
1-dependent pathways. J Allergy Clin Immunol. (2012) 130:195–204 e9.
doi: 10.1016/j.jaci.2012.02.042
79. Liu EM, Law HK, Lau YL. Mycobacterium bovis bacillus Calmette-Guerin
treated human cord blood monocyte-derived dendritic cells polarize naive
T cells into a tolerogenic phenotype in newborns. World J Pediatr. (2010)
6:132–40. doi: 10.1007/s12519-010-0019-0
80. Li G, Kim YJ, Broxmeyer HE. Macrophage colony-stimulating factor
drives cord blood monocyte differentiation into IL-10(high)IL-12absent
dendritic cells with tolerogenic potential. J Immunol (2005) 174:4706–17.
doi: 10.4049/jimmunol.174.8.4706
81. Matthews NC, Power UF, Reen DJ. Neonatal human autologous dendritic
cells pulsed with recombinant protein antigen prime the generation
of non-polarized CD4 T-cell effectors. Int Immunol (2007) 19:703–12.
doi: 10.1093/intimm/dxm025
82. Safdar A, Decker WK, Li S, Xing D, Robinson SN, Yang H, et al. De
novo T-lymphocyte responses against baculovirus-derived recombinant
influenzavirus hemagglutinin generated by a naive umbilical cord
blood model of dendritic cell vaccination. Vaccine (2009) 27:1479–84.
doi: 10.1016/j.vaccine.2009.01.017
83. Dinnis DM, James DC. Engineering mammalian cell factories for improved
recombinant monoclonal antibody production: lessons from nature?
Biotechnol Bioeng. (2005) 91:180–9. doi: 10.1002/bit.20499
Conflict of Interest Statement: Dr. Levy’s Lab has received sponsored research
support from 3M Drug Delivery Systems, MedImmune, and Crucell (Johnson
& Johnson). GS-S, CS, and OL are named on patent application entitled
Tissue Constructs and Uses Thereof (United States Application Serial No.
14/383,358) filed by Boston Children’s Hospital. DH is an employee of Adaptive
Biotechnologies.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2018 Sanchez-Schmitz, Stevens, Bettencourt, Flynn, Schmitz-Abe,
Metser, Hamm, Jensen, Benn and Levy. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 19 November 2018 | Volume 9 | Article 2634
